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ABSTRACT
This dissertation contains three parts based on my 
research project which investigates three aspects of rab­
bit muscle phosphofructokinase (ATP : D-fructose-6-phos- 
phate-1-phosphotransferase, EC 2.7.1,11; PFK). The first 
part reports the isolation and characterization of two 
full-length rabbit muscle PFK cDNAs. The DNA sequences 
of these two cDNAs (cDNA-A and cDNA-B) show an identical 
coding sequence but heterogeneous 5' untranslated 
regions. cDNA-A is formed by removal of a 1.7 Kb up­
stream intron while cDNA-B retains the 3' region of this 
intron.
The second part describes the expression of the cDNA 
in several bacterial hosts. Recombinant rabbit muscle 
PFK has been expressed at a significant level in a PFK 
deficient E. coll strain DF1020 using the plasmid pPL2 as 
the expression vector. This expression system provides a 
visible selection for clones which express rabbit muscle 
PFK. The recombinant PFK resembles the enzyme purified 
from rabbit muscle with respect to its affinity for 
substrates, its allosteric behavior and its physical 
properties.
The third part shows the structural and functional 
role of Gln-200 in rabbit muscle PFK (RMPFK). The 
comparison of the amino acid sequence of RMPFK to that of
xl
the PFK from Bacillus stearothermophilus suggests that 
Gln-200 of RMPFK is located in a region corresponding to 
the 6-F loop. This loop plays a critical role in the R-T 
transition of BsPFK. Mutation of RMPFK at position 200 
affects the apparent affinity of the enzyme for Fru 6-P 
under the conditions for which RMPFK behaves 
allosterically. Three mutations were made at position 
200: Gln-200 -► Arg <Q200R), Gln-200 Glu (Q200E), and
Gln-200 -* Ala (Q200A). The S Q . 5 ( F r u  6-P) of the Q200R
mutant is 4-fold lower than that of the wild type RMPFK.
The S Q 5 jFru g_p) of the Q200E mutant is increased about
14-fold. The Q200A mutant cannot achieve half­
saturation, even at a concentration of Fru 6-P over 200 
mM. Sigmoidal kinetics with respect to Fru 6-P were 
observed with Hill coefficients of 2.4, 1.9, and 1.0 for 
the wild type RMPFK and the Q200R and Q2Q0E mutants, re­
spectively. The data demonstrate that Gln-200 is a 
residue important for the cooperative binding of Fru 6-P 
to RMPFK.
xll
CHAPTER ONE 
INTRODUCTION
1.1. Background
Phosphofructokinase (PFK) (ATP : D-fructose-6-P-l 
phosphotransferase, EC 2.7.1.11) catalyzes the formation
of fructose 1,6-bisphosphate (Fru 1,6-P2> and ADP from
fructose 6-phosphate (Fru 6-P) and ATP (Figure 1). This 
constitutes a major regulatory step in the glycolytic 
pathway. The reaction catalyzed by PFK in muscle was 
first discovered by Ostern et al. (1936). Recognition of 
the rate-limiting role of PFK in frog muscle was initially 
made by Cori (1942). Lardy and Parks (1956) found that 
ATP is a potent inhibitor of partially-purified muscle 
PFK. ATP inhibition of PFK from rabbit tissues could be
relieved by Fru 6-P, Fru 1,6-P2 and AMP (Passonneau and
Lowry, 1963). It was found that the Fru 6-P saturation 
curve for most PFK isozymes from animal is sigmoidal (Pas­
sonneau and Lowry, 1963). This indicates the existence of 
cooperative interactions between subunits, and reveals the 
allosteric nature of this enzyme. Negative effectors 
decrease the affinity for Fru 6-P and positive effectors 
increase the affinity for Fru 6-P. Citrate, a metabolite 
which enhances intracellular coordination of glycolytic
1
2
H203POCHi^ ' ° \ ^  CHjOH h2o 3p o c h2
+ ATP ^. o .
CHjOPOjHj
», , _ . PhotpnormctcMunaM \  ^0 N  ■  f  OH o
OH H OH H
Fructow-6-phosphate Fructoaa-1,6-bisphosphata
Figure 1. PIT catalyzes the phosphorylation of fructosa 
6-phosphate to form fructose 1,6-bisphosphate.
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and mitochondrial ATP production, is another potent 
inhibitor of PFK (Garland and Randle, 1963; Parmeggiani 
and Bowman,1963). In the early-1980s fructose 2,6-
bisphosphate (Fru 2,6-P2)# an extremely potent activator
of PFK, was discovered by several research groups (Pilkis 
et al., 1961; Uyeda et al., 1981; Van Schaftingen et al.,
1960) . At low concentrations, 1 to 10 liM, this sugar 
bisphosphate can relieve ATP and citrate inhibition while 
increasing Fru-6-P affinity for various isozymes of mamma­
lian PFK (Uyeda et al., 1981; Van Schaftingen et al.,
1980a).
Numerous isozymes of PFK have been isolated from 
various animal tissues. In rabbits, three distinct PFK 
subunit types have been isolated and analyzed by 
polyacrylamide gel electrophoresis in the presence of 
sodium dodecyl sulfate (SDS-PAGE) (Foe and Kemp, 1984,
1985). These three types of subunit have been classified 
as M (muscle type), L (liver type) and C (brain type)
(Tsai and Kemp, 1974; Thrasher et al., 1981). Each sub­
unit has a molecular mass of 85000 ±  5000. A tetramer of 
these subunits is apparently the smallest active aggregate 
(Reinhart and Lardy, 1960). The relative abundances of 
these different PFK subunits in different tissues leads to 
the formation of tissue-specific patterns of homo- and 
heterotetrameric enzymes, which show different
4
immunochemical, chromatographic and regulatory properties 
(Dunaway, 1903; Foe and Kemp, 1985).
The kinetic properties and the physiological 
relevance of mammalian PFK isozymes have been subjects of 
intense research over the past 60 years. However, the 
knowledge of the structural properties of these PFK 
isozymes was obscure until the report of the amino acid 
sequence of rabbit muscle PFK (RMPFK) (Poorman et al.,
1904), which provided a breakthrough in PFK research.
Based on the information of the amino acid sequence of 
this enzyme, our laboratory was able to clone the RMPFK 
gene and to study its structure (Lee et al., 1987). Amino 
acid sequence comparisons of RMPFK with the prokaryotic 
enzyme indicate that the mammalian PFK probably evolved by 
duplication of and divergence from the prokaryotic gene 
(Poorman et al., 1984). Furthermore, possible substrate 
and effector sites in RMPFK have been assigned based on 
the crystallographic structure of bacterial PFK and a 
comparative sequence analysis (Poorman et al., 1984;
Hellinga and Evans, 1985). This putative structural model 
of RMPFK provided us a hypothetical basis for investigat­
ing the relationships of structure and function within the 
RMPFK enzyme. The accumulation of technological know-how 
together with the availability of DNA fragments of the 
RMPFK gene allowed us to clone and characterize the full 
length cDNA of RMPFK. This accomplishment opens two
5
fronts of PFK research to us: first, the characterization 
of the promoter region of the RMPFK gene and second, the 
investigation of the relationships between structure and 
function within this complex enzyme.
This dissertation consists of three parts. The 
first part presents the cloning and characterization of 
the full length cDNAs of RMPFK; the second part, the ex­
pression of cloned RMPFK cDNA in E. coli and the 
purification and characterization of the recombinant PFK; 
and the third part, the investigation of the allosteric 
properties of this enzyme by site-directed mutagenesis.
1.2. Studies on the Reaction Mechanism of PFK
Studies of the reaction mechanism of PFK are 
complicated by the fact that the PFK activity is influ­
enced allosterically by the concentrations of MgATP, Fru-
+2 xo6-P and free Mg . The influence of Mg can be minimized 
by using it in excess and treating the reaction as a two- 
substrate system (Uyeda, 1970). The substrates and prod­
ucts may exert regulatory effect as well as catalytic ef­
fects. Since mammalian PFK generally loses its suscepti­
bility to regulation as the pH becomes more alkaline 
(Uyeda, 1970; Uyeda, 1972; Hanson et al., 1973; Bloxham 
and Lardy, 1973), kinetic measurements are typically per­
formed above pH 8.0.
6
Uyeda (1972) reported evidence that the reaction 
mechanism of RMPFK is a sequential ordered mechanism.
Hanson et al. (1973), however, suggested the mechanism of 
RMPFK is a sequential random mechanism. Brand and Soling 
(1973) reported evidence that the mechanism of rat liver 
is sequential ordered.
The crucial factor in determining whether the reac­
tion mechanism of PFK is either sequential random or or­
dered is the product inhibition pattern of Fru 1,6-P2 with 
respect to Fru 6-P. The major difficulties with Fru 1,6- 
P2 are that it has multiple binding sites on the enzyme,
and it is also a potent allosteric activator of the en­
zyme. These factors plus other factors, such as free and
J.Obound Mg * concentration, affects PFK activity, which 
makes kinetic studies of reaction mechanism extremely dif­
ficult (Uyeda, 1979).
There is limited information about the reaction 
mechanism of bacterial PFK. Spaico and Anderson (1969) 
reported that the reaction mechanism of Aerobacter 
aerogenes is a sequential ordered mechanism. The studies 
on reaction mechanism of PFK from Lactobacillus easel and 
Lactobacillus plantrum also demonstrated that these en­
zymes exhibit sequential and ordered mechanism (Doelle,
1972). The binding of Fru-6-P and ATP to the minor E. 
coll PFK (PFK-2) is also sequential and ordered (Kotlarz
and Buc, 1981). Deville-Bonne et al. (1991) reported that 
the reaction mechanism of the major E. coli PFK (PFK-1) 
resembles that of muscle PFK (Hanson et al., 1973), and 
corresponds to a sequential mechanism for a random bireac­
tant system in rapid equilibrium (Segel, 1975; Cleland, 
1990).
1.3. Mechanisms of Cooporativity and Allostarie 
regulation in PFK
1.3.1. Properties and mechanisms of allosteric 
enxymes
Allosteric proteins control and coordinate chemical 
events in the living cell. By virtue of indirect interac­
tions between distinct binding sites mediated by the pro­
tein molecule, a protein's activity may be regulated by 
ligands dissimilar to its own substrate. The term homo­
tropic is used to denote the interactions among the iden­
tical substrate molecules, whereas the term heterotropic 
is used for the interactions of the allosteric effectors 
with substrates. A sigmoidal saturation curve is observed 
for the activity profile of an allosteric enzyme. The ef­
fect of the sigmoidal type of response is that the sub­
strate will tend to be held within more narrow confines of 
concentration.
Classical models of protein cooperativity are based 
on the concept of multiple equilibria between several
8
conformational states, ranging from a T state with low af­
finity to an R state with high affinity for substrates and
activators. The "concerted-symmetry" model of Monod,
Hyman, and Changeux (MWC model) predicts that the oligo­
meric enzyme can exist in either of two forms, T or R
(Monod et al., 1965), In the transition between them, the
symmetry of the molecule would be conserved, so that the 
activity of all its subunits would be either equally low 
or equally high. This assumption allowed the formulation 
of a mathematical model with only three independent vari­
ables: Kt and Kr, the dissociation constants of the ligand
with the protein in the T- and the R-structures, and Lo =
[T]/[R], the concentration ratio of the two structures in 
the absence of ligand. In homotropic allosteric activa­
tion, a substrate molecule may bind only to the more ac­
tive form (R form) of the enzyme. Thus, increasing the 
substrate concentration not only increases the fraction of 
substrate-bound enzyme form, but also shifts more of the 
enzyme into a more active form with all subunits in the R 
conformation. These effects lead to the increase in the 
rate of reaction. Effector alters the To/Ro ratio by 
preferentially stabilizing one of the forms. Activators 
bind preferentially to the R state. Inhibitors function 
by binding to the T state. The simplicity of this model 
provides a easy way to analyze data and explain phenomena.
9
The "sequential" model of Koshland, Nemethy, and 
Filmer (KNF model) is similar to the MWC model, but it al­
lows the two conformations of subunits to coexist within 
one oligomeric enzyme (Koshland et al., 1966). It assumes 
that the progress from the T to the ligand-bound R state 
is a sequential process. The conformation of each subunit 
changes in turn as it binds the ligand, and there is no 
dramatic switch from one state to another. The number of 
constants required is equal to the number of binding 
sites, unlike the situation in the MWC model, which always 
uses three.
1.3.2. Regulatory mechanism of bacterial PFKs
PFK from E, coli is a tetramer of 4 identical sub­
units that displays highly cooperative kinetics with re­
spect to Fru-6-P and hyperbolic kinetics with respect to 
ATP. In addition, it is activated by ADP or GDP, and is 
inhibited by phosphoenolpyruvate (PEP) (Blangy et al.,
1968). PFK from B, stearothermophilus behaves similarly, 
except that the kinetics with respect to Fru 6-P are sig­
moidal only in the presence of PEP; that is, the low- 
affinity state is only populated in the presence of PEP 
(Valdez et al., 1989). Structures of the high-affinity 
form (R state) and the low-affinity form (T state) have 
been well characterized for the enzymes from both species.
The homotropic cooperativity with respect to Fru 6-P will
10
be discussed in Section 1.4 in connection with the details 
of the crystal structures of the bacterial PFKs.
The steady-state kinetics of E. coli PFK were stud­
ied by Blangy et ai. (1968) and were among the first en­
zyme kinetics shown to fit to the MWC model of 
cooperativity (Monod et al., 1965). The R and T states of 
PFK had the same affinity for ATP, but the apparent affin­
ity for Fru 6-P of the R state was 2000 times higher than 
that of the T state (Table 1). In the absence of ligand,
PFK was mainly in the T state with the fraction of the 
protein in the R state being less than 10-6 (Table 1).
These states did not have the same affinity for the allos­
teric effectors: the activator ADP (or GDP) bound 
preferentially to the R state, and the inhibitor PEP bound 
to the T state. Thus, the activators ADP and GDP 
increased the affinity of PFK for Fru-6-P by favoring the 
R state, while the inhibitor PEP decreased this affinity 
by favoring the T state (Table 1). Neither GDP nor PEP 
altered the maximum rate of the reaction (Blangy et al.,
1968; Blangy 1971).
Some recent results have suggested, however, that a 
unique structural transition between the two states R and 
T of E. coli PFK could not account for both the homotropic 
allosteric effects and the heterotropic effects at the 
same time. First, the three-dimensional structure of un- 
liganded PFK resembled that of the R state (Rypniewsky and
11
Table 1
Thermodynaala paraaaters of X. coli PFK
Ligand Kr (M) kt <M)
ATP 6 x 10-5 6 x 1CT5
Fru-6-P 1.25 x ItT5 2.5 x 10"2
ADP 2.5 x 10"5 1.3 x 10~3
GDP 4 x 10"5 >4 x 10“2
PEP >7.5 x 10"1 7.5 x 10"4
Kr: dissociation constant of ligand in the R conformation 
Kt: dissociation constant of ligand in the T conformation 
N * 4 (number of protomers)
Lo ■ 1 x 10® (the equilibrium constant between the T state 
and R state in the absence of ligand)
c - KR(Fru-6-P) ̂ KT(F-6-P) 5 x (non-exclusive
binding coefficient)
(Adapted from Blangy et al., 1968)
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Evans, 1989), whereas the concerted model predicted that 
it should be in the T state- Second, the three- 
dimensional structures of the PFK from E. coli in the ab­
sence of effector (Rypniewsky and Evans, 1989) was similar 
to that from S. stearotbermophilus (Evans et al., 1981), 
which is mostly in the R state since its saturation by Fru 
6-P is hyperbolic (Valdez et al., 1989). Third, some mu­
tant PFKs had properties which were not easily accounted 
for by the concerted model (Lau and Fersht, 1987; Pertz,
1989; Berger and Evans, 1990). For example, the mutation 
of a single residue in the effector site, Glu-187 to Ala, 
led to PEP being an activator rather than an inhibitor 
(Lau and Fersht, 1987). With low concentrations of the 
substrate Fru 6-P, the mutant enzyme was 100 times more 
active than wild type enzyme at millimolar concentrations 
of PEP. According to the MWC model, PEP binds to the T 
state of wild type enzyme. But the effects of PEP on the 
mutant were consistent with PEP binding to an R state.
The data were not consistent with the conventional MWC 
model.
In addition to the information on the X-ray crystal 
structures of E. coli PFK and the kinetic data of the mu­
tant PFKs, the pH-dependence of the properties of E. coll 
PFK suggested that part of the cooperativity observed in 
saturation by Fru 6-P was of kinetic origin (Devilie-Bonne 
et al., 1991). The studies showed that the cooperativity
increases markedly with pH (in the range of pH 6.0 to pH 
9.0), reaching a value of Hill coefficient of n * 5.5-6.0 
at pH 9.0. Finding a value of the cooperativity coeffi­
cient larger than the number of substrate binding sites 
indicated that slow conformational changes may occur in 
PFK. The authors suggested that the MWC model may not be 
sufficient to describe the enzymatic properties of PFK.
More recently, Deville-Bonne and Garel (1992) have 
directly measured the binding of both substrates to PFK by 
equilibrium dialysis and by fluorescence changes to evalu­
ate the binding and kinetic contributions to the overall 
cooperativity observed for the saturation of E. coli PFK 
by Fru 6-P. Their studies demonstrated that the equilib­
rium data about ligand binding and conformational changes 
were consistent with a transition between two states, a 
low-fluorescence R state which bound the substrate Fru 6-P 
and the activator ADP and a high-fluorescence T state 
which bound the other substrate ATP and the inhibitor PEP, 
with a To/Ro around 2 for free PFK. These results are 
quite different from those described earlier for PFK from 
steady-state measurements (Blangy, 1968); the ratio 
between the two states, To/Ro, was around 4 X 10® for free 
PFK, and the the R and T states had the same apparent af­
finity for the other substrate, ATP. This major discrep­
ancy between thermodynamic and kinetic data suggested that 
contributions from both binding and catalysis are involved
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in allosteric control of activity (Deville-Bonne and 
Garel, 1992).
1.3.3. Regulatory properties of mammalian PFK
The major features of the regulation of mammalian 
PFK are as follows:
a) . Inhibition of the enzyme by high concentrations of
ATP. Generally, ATP decreases its affinity for Fru 6-P.
b). Inhibition by citrate. This inhibition is synergis­
tic with that of ATP.
c). Relief of the ATP inhibition by Pi, AMP, cAMP, ADP, 
Fru 6-P, Fru 1,6-P2 and Fru 2,6-P2*
d). Cooperativity of Fru 6-P binding. Negative effec­
tors decrease the affinity of PFK for Fru 6-P and positive 
effectors increase the affinity for Fru 6-P.
These four features represent the principal regula­
tory characteristics of various PFKs from mammalian 
sources. Their influence on the catalytic activity of PFK 
is such that changes in concentrations of the effectors 
occurring under physiological conditions enhance or re­
press PFK activity in accord with the physiological need 
for glycolytic intermediates and ATP.
Mammalian PFK exists as a pool of homo- or hetero- 
tetramers. The tissue-specific expression of various 
tetramers of PFK will be described in Section 1.4. The 
inhibitory action of ATP on RMPFK was first reported by
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Lardy and Parks in 1956. Increasing the concentration of 
ATP above that necessary for the optimum catalytic activi­
ty caused a progressive decrease in PFK activity. Mansour 
and Ahlfors (I960) showed that the inhibitory action of 
ATP is reduced as the concentration of Fru 6-P increased.
The physiological significance of this inhibition phenome­
non is obvious, since glycolysis serves to generate ATP in 
anaerobic cells and also provides oxidizable metabolites 
for mitochondria and aerobic cells. Moreover, the fact 
that the degradative products of ATP (i.e., AMP, ADP and 
Pi) relieve ATP inhibition further supports the importance 
of regulation of PFK activity by the energy status of a 
cell. Sensitivity to the ATP inhibition differs signifi­
cantly in relation to the source of PFK. The liver PFK is 
most strongly inhibited by ATP, the brain enzyme is less 
sensitive, and the muscle isozyme is least sensitive (Foe 
and Kemp, 1983).
The pH of the medium plays an important role in the 
ATP inhibition of PFK. Hanson et al.(1973) reported that 
RMPFK is inhibited by ATP and shows sigmoidal kinetics 
behavior with respect to Fru 6-P at pH 7.0 and saturating 
ATP concentration. However, inhibition by ATP and cooper­
ativity in Fru 6-P kinetics of this enzyme are not present 
at pH 8.0. Similar behavior is observed for PFKs from 
brain (Lowry and Passonneau, 1966; Tsai and Kemp, 1974)
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diaphragm (Ui, 1966) , heart (Mansour and Ahlfors, 1968) , 
liver (Kemp, 1971), and placenta (Kahn et al., 1979).
The second major inhibitor of mammalian PFK is 
citrate. Citrate binds to the inactive form of PFK and 
acts synergistically with ATP to displace the equilibrium 
away from the R-state. This reveals the link between gly­
colysis and TCA cycle (Garland et al., 1963; Tsai and 
Kemp, 1974), Phosphocreatine, 3-phosphoglycerate, 2-phos- 
phoglycerate, 2,3-bisphosphoglycerate are all inhibitors 
of eukaryotic PFKs (Bloxham and Lardy, 1973; Uyeda, 1979).
The inhibition by these phosphorylated intermediates of 
glycolysis is most pronounced below neutral pH and in the 
presence of inhibitory concentrations of ATP (Colombo et 
al., 1975). On the other hand, AMP, cAMP, ADP, Pi, Fru 6-
P, Fru 1,6-P2 and Fru 2,6-P2 relieve or counteract the in­
hibition of PFKs by ATP and negative effectors (Uyeda,
1979; Pilkis et al., 1981).
The physiological activity of some mammalian PFK is 
sensitive to hormonal changes. The ability of glucagon to 
inhibit liver PFK was observed by Taunton and his 
coworkers (1974). Exton (1970) demonstrated that the 
short-term effect of insulin in the liver is to counteract 
the action of a small dose of glucagon. Early studies 
suggested that these hormones probably affect the cAMP-me- 
diated phosphorylation of PFK (Taunton et al., 1974; Brand 
and Soling, 1973). Cyclic AMP-dependent protein
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kinase-catalyzed phosphorylation at a seryl residue in the 
C-terminal region of skeletal muscle PFK has been reported 
by Riguelme, et al. (1978). However the regulatory 
properties of the phosphorylated PFK are not much differ­
ent from those of the dephosphorylated enzyme (Foe and 
Kemp, 1982). The physiological relevance of phosphoryla­
tion of glycolytic and gluconeogenic enzymes has been 
reviewed by Pilkis and his colleagues (1988).
The discovery of Fru 2,6-P2 provided a clear
explanation for the physiological regulation of PFK. Fru
2.6-P2 has the ability to stimulate all mammalian PFKs
that have been tested (Van Schaftingen, 1980a, 19B0b;
Uyeda, 1981; Pilkis, 1981), including those extracted from 
cells, such as erythrocytes, that do not contain fructose
2.6-bisphosphate. The main characteristics of this stimu­
lator were first described for the liver enzyme (Uyeda, et 
al, 1981; Van Schaftingen et al., 1981a). It acts 
synergistically with AMP to oppose the inhibitory action 
of ATP and citrate (Pilkis, 1981; Uyeda, 1982; Claus,
1983). It is well known that PFK is also stimulated by
Fru 1,6-P2. For the liver enzyme, the concentration of
Fru 2,6-P2 needed to obtain a half-maximal stimulation is
1000 times lower than the concentration of Fru 1,6-P2 re­
quired to reach the same effect (Van Schaftingen et al.,
1980a). Studies by Foe et al. (1983) and by Kitajima and
Uyeda (1983) have shown that Fru 2,6-P2 binds to rabbit
muscle PFK with an approximately 10-fold higher affinity
than does Fru 1,6-P2* These two fructose bisphosphates
antagonize each other's binding. This indicates that Fru
2,6-p2 and Fru 1,6-P2 probably bind to the same allosteric
site (Foe et al., 1983).
In rat skeletal muscle, insulin and epinephrine, 
both of which stimulate lactate production, have been
shown to increase the levels of Fru 2,6-P2 (Hue et al., 
1982; Bosca et al., 1985). Bosca and co-workers (1985) 
have proposed that the rise in Fru 2,6-p2 concentration 
induced by epinephrine and insulin could enhance cycling 
between Fru 6-P and Fru 1,6-P2* PFK catalyzes the phos­
phorylation of Fru 6-P to Fru 1,6-P2 in glycolysis. On 
the other hand, fructose 1,6-bisphosphatase catalyzes the 
hydrolysis of Fru 1,6-P2 to give Fru 6-P and orthorphos-
phate during gluconeogenesis. Regulation at the 6-phos- 
phofructo-1 kinase/fructo-1,6-bisphosphatase is now 
thought to be mediated primarily by changes in the level
of Fru 2,6-P2 (Claus et al, 1984; Hue, 1987; Pilkis et 
al., 1987). In states where Fru 2,6-P2 levels are high,
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the activity of PFK and flux through the glycolytic 
pathway are high, and fructose 1,6-bisphosphatase activity
is inhibited. On the other hand, when Fru 2,6-p2 levels
are low, fructose 1,6-bisphosphatase activity is enhanced,
PFK activity is inhibited, and the gluconeogenic flux pre­
dominates. Fru 2,6-P2 can be thought of as a master 
switching signal between gluconeogenesis and glycolysis.
Fru 2,6-P2 is formed by the phosphorylation of Fru
6-P, in a reaction catalyzed by 6-phosphofructo-2-kinase, 
an enzyme distinct from 6-phosphofructo-l-kinase (PFK).
It is hydrolyzed to Fru 6-P by a specific phosphatase,
Fructose-2,6-bisphosphatase. The level of Fru 2,6-P2 is
determined by the balance between the activities of 6- 
phosphofructo-2-kinase and fructose-2,6-bisphosphatase.
It is indeed a striking finding that 6-phosphofructo-2-ki- 
nase and fructose-2,6-bisphosphatase activities are both 
present within a single 53 KD polypeptide chain (El- 
Magharabi et al., 1962; Tauler et al., 1988). This bi­
functional enzyme is phosphorylated by the cAMP-dependent 
protein kinase (Murray et al., 1984). Phosphorylation of 
a single seryl residue per enzyme subunit results in both 
a decrease in kinase activity and an increase in 
phosphatase activity (El-Maghrabi et al, 1982; Van Schaft­
ingen et al., 1983, Kurland et al., 1992).
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In addition to the allosteric regulation by AMP/ATP,
citrate and Fru 2,6-P2f the synthesis of 6-phosphofructo-
1-Jcinase is also regulated at the level of transcription.
Mouse liver PFK mRNA synthesis has been shown to be under 
hormonal, dietary and developmental control (Gehnrich et 
al., 1988). Gekakis et al (1989) have shown that both an 
induction of mouse muscle PFK enzyme synthesis and an in­
crease in mRNA concentration during myoblast differentia­
tion.
1.3.4. Molecular mechanism for the sigmoidal 
kinetics of RMPFK
The molecular mechanism for the cooperative binding 
of Fru 6-P by RMPFK is not fully understood. Hill and 
Hammes (1975) studied the binding isotherms of Fru 6-P and
Fru l,6-p2 at different pH's. At pH 7.0, the binding iso­
therms for Fru 6-P and Fru l,6-?2 exhibit negative
cooperativity; at this pH, PFK exists as a mixture of 
dimers and tetramers. At pH 8.0, the negative cooperativ­
ity is less, and PFK is proposed to exist primarily as 
tetramers. At protein concentrations for which polymers
larger than the tetramer predominate, Fru 1,6-P2 binding
is hyperbolic. Because the negative cooperativity of Fru 
6-P binding to the enzyme is less in the tetramer than in
the dimer, there is a conversion of dimer to tetramer as 
the enzyme is saturated with Fru 6-P.
The above binding studies were done in the absence 
of ATP or its analogs. In the presence of an ATP analog, 
however, Fru 6-P binding is positively cooperative. The 
results fit a sequential mechanism (Koshland et al., 1966) 
more closely than a two states mechanism (see below).
Such a mechanism explains the negative cooperativity more 
adequately (Hill and Hammes, 1975).
Bock and Frieden (1976) offered an alternate expla­
nation for the binding isotherm for Fru 6-P based on their 
studies of the effect of pH on RMPFK. Their studies 
demonstrated that the degree of regulatory kinetic behav­
ior of RMPFK increases with lower pH values at a given 
temperature. They postulated a model analogous to the 
concerted model (Monod et al., 1965), in which two forms 
of RMPFK exist, one protonated and the other not. Fru 6-P 
binds preferentially to the unprotonated form, while ATP 
and citrate bind to the protonated form. Thus, upon low­
ering pH, regulatory behavior increases (Boch and Frieden, 
1976; Frieden et al., 1976).
Because the experimental conditions, including pro­
tein concentration and the presence or absence of ligands 
are different for each study, it is difficult to correlate 
the results of ligand binding and the resulting ligand-in­
duced conformational changes with the kinetic properties.
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There Is no adequate model which can explain the mechanism 
for the allosteric transition of RMPFK at this time.
1.4 Tissue Specificity of Mammalian PFK
The existence of multiple forms of PFK from various 
mammalian tissues has been reported. Animal PFK can exist 
as a tetramer of molecular mass around 340,000. Different 
isozymes are present in different animal tissues. They 
result from the assembly of three types of subunits; M for 
muscle type, L for liver and C for brain (Dunaway, 1983).
PFK isolated from muscle is a homotetramer of M-subunits, 
whereas in liver and placenta, it is a mixture of tetram­
ers with the L4-homotetramer as the major component. In 
fibroblasts, platelets and brain cells, PFK exist predomi­
nantly as the C4-isozyme with other heterotetramers as 
minor components. The hybrid isozymes are distinguishable 
from one another by the differences in their immunoprecip- 
itation and kinetic properties (Dunaway, 1983; Foe and 
Kemp, 1985). In addition, the three subunit types can be 
separated by SDS-polyacrylamide gel electrophoresis.
Several groups of investigators have been successful in 
raising subunit-type specific antibodies (Dunaway, 1903).
Dunaway and co-workers (Dunaway et al., 1988) ana­
lyzed various human tissues for PFK subunit composition, 
and determined the kinetic and regulatory properties of 
these PFK isozymes. All three isozymes exhibited a
sigmoidal response to increasing concentration of Fru 6-P, 
and a sensitivity to ATP inhibition. However, the 
isozymes are all kinetically distinct from one another.
The M4-homotetramer has the highest affinity for Fru 6-P.
Fru 2,6-P2 substantially enhances the affinity of the bl­
and L- rich isozymes for Fru 6-P. PFK composed solely of 
C subunit, however, is much less sensitive to Fru 2,6-P2.
Differences in kinetic and allosteric behavior of the var­
ious tetramers allow tissue-specific regulation of PFK ac­
tivity. Thus, the rate of glycolysis is uniquely 
controlled in muscle, liver and brain.
1,5. Structure of PFK
1.5.1. Sequence comparison of mammalian PFKs
The structural properties of PFK from eukaryotes are 
as interesting and complex as its kinetic properties. For 
most mammalian PFKs, the molecular weight of the subunit 
is approximately 85000 +. 5000. The primary structures of 
the rabbit muscle PFK (Poorman et al., 1984; Lee et al., 
1987), the human muscle PFK (Nakajima et al., 1987), the 
mouse liver PFK (Gehnrich et al., 1988), and the human 
liver PFK (Levanon, 1989) have been determined either by 
direct peptide sequencing, or by inference from the gene 
or cDNA sequences (Fig. 2). Gehnrich et al. (1988) re­
ported that the amino acid sequence homology between the
rigura 2. Comparison of ths amino acid saquancas of human livar, mousa livar, and rabbit muscla PFK. Dashes 
represent identity with the human liver PFK. Rabbit mus­
cle (RMPFK) sequence is from Lee et al. (1987). Mouse 
liver PFK (MLPFK) sequence is from Gehnrich (1988). Human 
liver (HLPFK) sequence is from Levanon et al. (1989) . 
(Adapted from Levanon et al.r 198 9)
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mouse liver PFK and the rabbit muscle PFK is 68%. The 
genes of the two muscle-type or of the two liver-type en­
zymes from mouse and the rabbit have about 90% identity in 
nucleotide sequences within the coding region. However, 
the degree of sequence similarity between the amino acid 
sequences of human liver PFK and human muscle PFK is only 
68% (Levanon et al., 1989) (Fig. 2). Therefore, it ap­
pears that the sequence of same type of PFK isozyme are 
more conserved between mammalian species than among 
isozymes in the same species.
1.5.2. Sequence comparison of amino and carboxy
halves of BMPFK and those of bacterial PFK
Similarities in the amino acid sequences between the 
PFK of B. stearothermophllus (BsPFK) and the amino and 
carboxyl halves of rabbit muscle PFK (Figure 3) were no­
ticed by Poorman et al. (1984). The respective identities 
for each comparison are 44% (BsPFK vs N-half), 34 % (BsPFK 
vs C-half) and 32 % (N-half vs C-half). Therefore, they 
have suggested that the mammalian PFK evolved from bacte­
rial PFK by gene duplication and divergence. This dupli­
cation pattern is also observed in mouse liver PFK, human 
liver PFK and even yeast PFK (Heinisch et al., 1989).
Based on this hypothetical evolutionary pathway and the 
knowledge of the crystallographic structure of B, 
stearothermophllus PFK (Kolb et al., 1980), a model
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explaining the tertiary structure and the function of 
RMPFK has been proposed (Poorman et al., 1984) (Fig. 4).
The hypothetical tetramer of RMPFK shows the puta­
tive catalytic and regulatory sites. Residues involved in 
these sites are located in the interface between subunits 
or between the N- and C- halves of the same subunit. The 
roles of these amino acid residues have been proposed on 
the basis of sequence homologies between bacterial PFK and 
N- and C- halves of RMPFK (Poorman et al., 1984; Evans,
1985) (Table 2). The N- half of RMPFK preserves most of 
the critical catalytic residues found in bacterial enzymes 
but some of the corresponding residues in the C- half are 
not conserved. In particular, this latter half has lost 
the catalytic residue Asp-127, but preserved most of the 
Fru-6-P binding residues, suggesting that the C- half has 
lost its catalytic function and instead has become a
regulatory domain which binds Fru-2,6-P2 or other
effectors. The effector site is less well conserved be­
tween the bacterial and rabbit muscle enzymes, which is 
consistent with their having different allosteric effec­
tors.
1.5.3. Three-dimensional structures of bacterial 
PFK
The crystal structures of the PFK from B. 
stearothermophllus and of the major PFK isozyme from
Figure 3. The amino acid aaquancaa of the N- and C- halvas of rabbit muacla PFK (RMPFK) compared with thosa of B. Stearothexmcphllu* PFK (BsPFK) and f. coil PFK-1 (Ic PFK-t). Double-headed arrows (above all the sequences) 
represent the secondary structure elements found In the 
structure of B. Stearothermophllus enzyme. Numbers are 
corresponding to the positions of residues in BsPFK. Un­
derlined residues are those deduced from DNA sequence of 
RMPFK gene (Modified from Hellinga and Evans, 1985).
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C-HALF, SUBUNIT 2
N-HALF, SUBUNIT t
B
N- AND C-HALVES OF A SINGLE SUBUNIT
m
Figure 4. Location of substrata and affactor sitas in BMP IK basad on crystallographic analysis of BsPFK and com­parative sequence analysis. Residues enclosed in solid 
boxes are identical to those at corresponding positions in 
BsPFK; those enclosed in dotted boxes are different. 
Numbers 1 and 2 represent the domains in a single subunit. 
A. View along the z-dyad axis of the N- and C- halves of 
the two adjacent subunits which together define sites for 
cooperative binding of Fru-6-P (F6P) and fructose bisphos- 
phates (FBP). Dotted lines between residues indicate pos­
sible hydrogen bonds. B. View along the x-dyad axis of 
the halves of a single RMPFK subunit in which residues 
presumed to be involved in binding ADP activator and ATP 
inhibitor are noted. The solid bar labeled 'connecting 
peptide' represents the covalent bridge between the halves 
related by the x-dyad axis. (Adapted from Poorman et al.,
1984) .
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Tsble 2A comparison of rasiduas in tha ligand binding sitas of thraa ralatad PFKs: EcPrK-1 (Ec), BsPFK (Bs) , and tha N- tarminal and C-taxminal halvas of RMPFK [RM{N) and RM<C)] .
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Residue are listed under their number in the BsPFK 
sequence. Residues contributing to site A and C are di­
vided between neighboring subunits in the tetramer. Resi­
dues marked * are not in the subunit containing the main 
part of the site. The dyad symmetry axis relating the 
subunit containing the main site are given as (p) or <r) . 
(Adapted from Hellinga and Evans, 19B5)
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E. coli have been solved by Evans and his colleagues 
(Evans and Hundson, 1979; Evans et al., 1986; Schirakihara 
and Evans, 1988; Schirmer and Evans, 1989; Schlrmer and 
Evans, 1990). The molecular mechanism for the transition 
between the R (Relaxed) and T (Tight) conformations of 
PFK is beginning to be understood from the recent results 
of the crystal structure of BsPFK (Schirmer and Evans, 
1989, 1990). The R and T states of PFK differ primarily 
in their quaternary structure: one pair of subunits in the 
tetramer is rotated 7° with respect to the other pair of 
subunits. The restructuring of the 6-F loop is closely 
correlated with the rotation of the dimers relative to 
each other (Schirmer and Evans, 1990) (Fig. 5).
The binding site for the cooperative substrate Fru 
6-P is altered by the change involving the 6-F loop 
(Schirmer and Evans, 1990) (Fig. 6). In the R state, a 
major part of the binding energy comes from Arg-162 and 
Arg-243 across the subunit interface (Fig. 6B). However, 
Arg-162 swings around away from the active site in the T 
state. Glu-161, in turn, adopts the former (R state) 
position of Arg-162 and forms a salt bridge with Arg-243 
(Fig 6A). The positive charges of Arg-162 and Arg-243 are 
no longer available for binding to the negatively charged 
phosphate of Fru 6-P. This in part accounts for the large 
decrease in the affinity for Fru 6-P. In E. coli PFK-1,
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R
T
Tigura 5. G a n m l  viav of BsPFK and its quaternary and tertiary structure changes on the allosteric transitionfrom R to T. a. Schematic sketch of the R-state (dashed 
outline) and Testate (solid outline) PFK tetramer, viewed 
along r. The three mutual perpendicular 2-fold symmetry 
axes are labeled p, q and r. The subunits are labeled A-
0. Residues labeled with * belong to subunit A, all 
others to subunit D. b. R-state structure, subunit A and 
D, related by r dyad as view as in a. Helices are repre­
sented as cylinders numbered 1-13, 0-sheet strands are ar­
rows labeled A-K. In the active site the substrate Fru-6- 
P (F6P) and the product ADP are shown, in the effector 
site the activator ADP is shown. (Schirmer and Evans, 
1990) (Reprinted by permission from Nature vol. 343, 
pp.140-145; Copyright (c) 1990 Macmillan Magazines Limit­
ed)
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Figure 6. Schematic view of the 6-F loop (155-162) in BsPFK showing its diffsrsnt intsrsctions scross the inter-fscs between dinars. The wavy line represents part of the 
boundary between r-dyad-related subunits (that is, the 
boundary between dimers). a. T-structure, showing Glu 161 
in the Fru-6-P binding site, the Arg 72-Glu 241 salt 
bridge. b. R-structure ( with bound ligands ADP and Fru- 
6-P), showing the phosphate of Fru-6-P bound by Arg 162 
and Arg 243. (Schirmer and Evans, 1990) (Reprinted by 
permission from Nature vol. 343, pp.140-145; Copyright (c) 
1990 Macmillan Magazines Limited)
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residue 161 is Gin, so the charge change would be less 
during the R to T transition.
Kinetic data have shown that Arg-162 and Arg-243 are 
important residues in the T to R transition of E. coli 
PFK-1 (Berger and Evans, 1990) . Residues 156-160, which 
are located in the 6-F loop of E. coli PFK-1, also have 
been shown to be critical in the T to R transition (Kun- 
drot and Evans, 1991).
1.5.4. Structural comparison of bacterial PFK and 
rabbit muscle glycogen phosphorylase
High resolution refined structures are available for 
the T and the R states for four allosteric proteins: 
hemoglobin, E. coli aspartate transcarbamoylase, bacterial 
PFK, and rabbit muscle glycogen phosphorylase. In this 
section, a structural comparison between bacterial PFK and 
rabbit muscle glycogen phosphorylase was chosen because in 
both bacterial PFK and rabbit muscle glycogen phosphory­
lase, concerted movements of a basic group and an acidic 
group create a phosphate recognition site (Johnson and 
Barford, 1990).
Bacterial PFK and rabbit muscle glycogen phosphory­
lase have very different subunit-subunit interfaces. 
Furthermore, the types of secondary structures involved in 
their subunit-subunit interfaces do not share any common 
features (Johnson and Barford, 1990). However, a
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structural comparison of these two allosteric proteins may 
provide the information to understand how tertiary struc­
tural changes associated with ligand binding closely 
correlated with quaternary structural changes.
Glycogen phosphorylase (GP) catalyzes the degrada­
tion of intracellular glycogen. The enzyme is a dimer of 
two identical subunits. It exhibits homotropic effects 
for binding of substrates and AMP, as well as heterotropic 
effects (Black and Wang, 1968). Comparison of the T and 
the R structures of PFK and GP shows that the conforma­
tional response at the ligand binding sites are small 
(Johnson and Barford, 1990). There are concerted move­
ments of a basic group and an acidic group to create a 
phosphate recognition site in both proteins (Arg-162 and 
Glu-161 for PFK; Arg-569 and Asp-283 for GP) (Schirmer and 
Evans, 1990; Barford and Johnson, 1989).
The mechanism for transmission of homotropic effects 
is different between the two enzyme molecules. In PFK the 
substrate binding sites are at the subunit interface, and 
changes in tertiary structure are directly involved in 
quaternary changes at the subunit interface (Schirmer and 
Evans, 1990). In GP, however, tertiary structural changes 
are not directly associated with the quaternary structural 
changes (Johnson and Barford, 1990). The substrate sites 
are buried within the subunits, and ligand-induced changes
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in tertiary structure promote indirect long distance 
changes at the interface (Barford and Johnson, 1989).
The locations of the effector sites involved in 
heterotropic interactions also reveal differences between 
these two enzymes. In PFK, the regulatory sites are at a 
rigid subunit interface and transmit a signal through 
changes in tertiary structure to the substrate binding 
site interface (Schirmer and Evans, 1990; Johnson and Bar­
ford, 1990). In GP, the regulatory sites are at subunit 
interfaces (Barford and Johnson, 1989). Structural stud­
ies of the allosteric transitions of these two allosteric 
enzymes provide the information to explain how two binding 
sites located far away can communicate with each other.
1.6. Rationale and Objective
1.6.1. 5' untranslated region of RMPIT gene
Mammalian PFK has three types of subunits which as­
sociate to form different homotetrameric or heterotet- 
rameric isozymes whose catalytic activities and regulation 
properties are influenced by their composition (Dunaway,
1983; Foe and Kemp, 1985; Dunaway et al., 1988). To 
understand the tissue-specific abundances of these 
isozymes, it is important to have a knowledge of the 
structures of the different isozyme genes. The gene 
structure of RMPFK has been well studied by Lee et al 
(1987), but the sequence in the promoter region of this
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gene has not been determined. The isolation of the rabbit 
muscle PFK cDNA reported here provides the sequence 
downstream of the transcription initiation site in the 5'- 
untranslated region of RMPFK gene. This paves the way for 
further characterization of the transcription start site 
(sites) in the promoter region of this gene.
1.6.2. Structure-function relationships of RMPFK
The kinetic properties and the physiological 
relevance of mammalian PFK isozymes have been thoroughly 
studied. However, structure/function relationships for 
these isozymes have not been elucidated. The accomplish­
ment of the expression of the cloned RMPFK in E. coll 
cells should provide us with powerful tools to investigate 
the structural/functional properties of muscle-type PFK 
from a new perspective. Crystallographic studies on BsPFK 
have shown a switch between Arg-162 and Glu-161 at the 
Fru-6-P binding site during the R-T transition (Schirmer 
and Evans, 1990). The allosterically inhibited BsPFK 
shows subunit twisting that limits the access of Fru 6-P 
to its binding site. Sequence alignment of RMPFK with 
BsPFK (Figure 3) suggests that Gln-200 and Arg-201 in 
RMPFK are equivalent to Glu-161 and Arg-162 in BsPFK. On 
the basis of the crystal structure of BsPFK and the se­
quence alignment between BsPFK and RMPFK, experiments were 
designed to investigate the structural role of Gln-200 in
the R-T transition of RMPFK. Mutation at Gln-200 may 
either enhance or reduce the affinity for Fru-6-P binding 
This mutation may also strengthen or weaken subunit inter 
action, in this study, Gln-200 has been mutated to 
alanine, arginine, and glutamate to determine how the 
charge and the size of the side chain at residue 200 
affect the kinetic properties of this enzyme. The specif 
ic aims of this study are the following:
1. To clone the cDNA encoding rabbit muscle PFK.
2. To express the cloned RMPFK in an E. coli expression 
system and to purify it.
3. To compare kinetic properties of authentic RMPFK and 
cloned RMPFK.
4. To determine the structural and functional role of Gin 
200 in the R-T transition of RMPFK by mutation of Gln-200 
to alanine, arginine, asparagine and glutamic acid.
CHAPTER TWO 
MATERIALS AND METHODS
2.1. Materials
2.1.1. Enzymes and antibody
Restriction endonucleases, DNA ligase, exo nuclease 
III, mung bean nuclease, DNA kinase, T4 DNA polymerase were 
purchased from Bethesda Research Laboratories (BRL) 
(Bethesda,MD), Boehringer-Mannheim Biochemicals (Indianapo­
lis, IN), New England Biolabs, Inc. (NEB) (Boverly,MA), 
Promega Biotec Corporation (Madison, HI), and Pharmacia 
(Piscataway, NJ). Nick translation kits and sequenase kits 
were obtained from United States Biochemicals Corp. (USB) 
(Cleveland, OH). Taq DNA polymerase kits were ordered from 
Perkin Elmer Cetus (Norwalk, CT). In vitro mutagenesis kit 
was from Promega Biotec Corporation. RNAse A, protein-A, 
aldolase (Type IV), mixture of triose-phosphate isomerase 
and glycerol 3-phosphate dehydrogenase (Type III) were pur­
chased from Sigma Chemical Co. (St Louis, MO). Antiserum 
against rabbit muscle phosphofructokinase was a gift from 
Dr. Dunaway (Southern Illinois University).
2.1.2. Chemicals
Bacto-tryptone, bacto-yeast extract, and bacto-agar 
were purchased from Difco Laboratory (Detroit, MI).
Agarose, low melting point Seaplaque agarose, urea and
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phenol were obtained from BRL or American Research Products 
Company (AMRESCO) (Solon, OH). Acrylamide, N,N'-methylene- 
bisacrylamide,, acrylamide stock solution (40 %, w/v) (ACR- 
YL-40) and N,N'-methyllene-bis-acrylamide stock solution (2 
%, w/v) (BIS-2) were ordered from AMRESCO. Tris-(hydroxym- 
ethyl) aminomethane (Tris), Tris-(hydroxyethyl) ethanesu- 
fonic acid, ethylenediaminetetraacetic acid (EDTA), nicoti­
namide adenine dinucleotide (reduced form, NADH), sodium 
dodecyl sulfate (SDS), polyethyleneglycol (PEG), phenylme- 
thylsulfonyl fluoride (PMSF), fructose 6-phosphate (sodium 
salt), fructose 2,6-bisphosphate, adenosine triphosphate 
(sodium salt), adenosine monophosphate (sodium salt), 
sodium citrate, phosphenolpyruvate, creatine phosphate, 
dithiothreitol, 5-bromo-4-cloro-3-indolyl-b-D-galactoside 
(X-gal), isopropyl-b-D thiogalactopyranoside (IPTG), ampi- 
cillin, kanomycin and chloramphenicol were purchased from 
Sigma Chemical Co. Columns packed with Sephadex G-50 and 
G-25 (Select D) were obtained from 5 Prime - 3 Prime, Inc. 
(West Chester, PA). Gene clean kit was bought from Bio 
101, Inc. (Lo Jolla, CA). Nitrocellulose filters were or­
dered from Schleicher and Schuell (Keene, NH). Polyethyle- 
neimine cellulose F plates were purchased from EM Science 
(Gibbstown, NJ). Whatman 3MM filter papers were obtained 
from Fisher Scientific (Pittsburgh, PA). DEAE cellulose 
(DE 52) was bought from Whatman (Hillsboro, OR). Cibacron 
blue F3GA-Agarose was ordered from Pierce (Rackford, IL).
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Polaroid film was purchased from Polaroid Co. Filins XAR-5 
and XRP-5 was from Eastman Kodak Co.( Rochester, NY).
2.1.3. Radioactive compounds and oligonucleotides
[a-^PJ-dCTP, [y-32P]-ATP, [a-35S]-dATP and 125I were 
purchased from ICN Biomedicals, Inc. (Irvine, CA) and New 
England Nuclear (NEN)/Dupont Co. (Wilmington, DE). 
Oligonucleotides were synthesized by solid support 
phosphite chemistry (Matteucci and Caruthers, 1981) in an 
automated DNA synthesizer (Applied Biosystems Model 380A) 
or ordered from American Synthesis Inc. (Pleasanton, CA).
2.1.4. Vectors, helper phage and bacterial strains
The Lambda ZAP II library containing rabbit muscle 
cDNAs, pBluescript KS(+) and KS(-) were purchased from 
Stratagene (Lo Jolla, CA). M13mpl6 and ml3mpl9 were or­
dered from Boehringer-Mannheim Biochemicals. The expres­
sion vector with the bacteriophage T7 promoter (pET-3c) and 
the plasmid carrying the T7 lysozyme gene (Studier et al., 
1990) were gifts from Dr. B. Valdez (Baylor College of 
Medicine, Houston, TX). The expression vector with the 
lambda PL promoter (pPL2) and the plasmid with a cI857ts 
gene (pCI857) (Drahos and Sybalski, 1981) were gifts from 
Khorana (MIT, MA). The in vitro mutagenesis vectors 
pSELECT-1 and pSELECTE-control were obtained from Promega
43
Biotec Corporation. Helper phage R408 was purchased from 
Stratagene and Promega Biotec Corporation.
The bacterial strains used in this work and their 
genotypes are listed in Table 2. E. coli strains HMS174 
and BL21(Studier and Moffatt, 1986) were gifts from Dr. B. 
Valdez. E. coli strain DF1020 was kindly provided by Dr. 
Barbara Bachmann of the E. coli Genetic Stock Center (Yale 
University School of Medicine, New Haven, CT>.
Table 3 
Bacterial Strains
E. coll 
Strain
Genotype Reference 
or Source
XLl-Blue endAl, hsdR17 (rk“, ink ), supE44, 
thi-1, lambda”, recA, gyrA96, 
relAl, (Iac~*[F', proAB, IacIqZ 
M15,TnlO(tetR)].
HMS174 F" recA rK12~mK12+ RifR
Stratagene 
Cat. No. 
236211
Studier
1990
BL21 F~ ompT rB“mB' Studier
1990
DHSOF1
DH5a
M5219
DF1020
JM109
F', endAl, hsdR17, (rR“,mR ) supE44, 
thi-1, recAl, gryA96, relAl, , 
4>80dlacZ _ Ml5 (iacZYAargF) U169
F-, endAl, hsdR17 (rK~'mK+*f supE44, 
thi-1,recAl, relAl, gyrA96, relAl,
BRL 
Cat. No. 
8264SA
BRL 
Cat. No.
(argF~ laczya)U169, (pSOdlacZ M15, X 8265SA
N+, F' lacZ, trp, SnP~, gall3, chi, 
bio, uvrB, (XN7N53cI857H1)
pro-82, pfkB201, recA56,
{rha-pfkA)200, endAl, hsdR17, 
supE44, thi-1
endAl, recAl, gyrA96, thi, hsdR17, 
{rK”,JrtK_), relAl,supE44, X~, 
(lac-proAB),
[F', traD36, proAB, lacIqZ M15]
Remaut 
et al.,
1981
Kotlarz 
et al.,
1982
Promega 
cat. No. 
Q6210
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Table 3 continued
BMH 71-18 thi, supE, (Iac“proAB) , [mutS::TnlO] Promega
mutS [F', proA+B+, lacIqZ M15} Cat. No,
Q6210
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2.2 Methods
2.2.1. Cloning and sequencing of RMPFK cDNAs
A lambda ZAP II cDMA library of rabbit muscle was 
screened using a partial C-terminal RMPFK cDNA fragment and 
a N-terminal RMPFK genomic DNA (exon I) as DNA probes. The 
in vivo excision method was used to excise the pBluescript 
phagemid carrying RMPFK cDNA from the lambda vector. The 
RMPFK cDNA inserts were characterized in a plasmid system 
by endonuclease mapping and Southern blotting. Nested 
deletion constructs of RMPFK cDNAs were prepared by using 
the ExoIII nuclease and Mung Bean nuclease system. Some 
partial RMPFK cDNA fragments were sucloned from pBluescrip- 
tRMPFK to M13. Double stranded and single stranded dideoxy 
sequencing methods were used to sequence the deletion 
constructs and the partial fragments of RMPFK cDNAs.
2.2.1.1. Screening of RMPFK cDNAs
A Schematic diagram of the cloning of RMPFK cDNAs 
from a lambda ZAPII cDNA library is shown in Figure 7. The 
details of DNA screening and DNA preparation protocols are 
described in Appendix VI. £. coli XLl-Blue cells were
infected with bacteriophage X ZAP and plated on NZY plates. 
Approximately 50,000 plaques were plated on a large 150 mm 
plate. Twenty plates were used to screen 1 x 10® plaques.
The plaques were transfered onto nitrocellulose filters in 
duplicates. A nick translated DNA probe corresponding to
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Figure 7 Schematic diagram of isolation of rabbit muscle 
PFK CDMA from a XZAFIX cDNA library.
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the 3' end of RMPFK cDNA was used to hybridize the filters 
for screening. Positive plaques, totally 122, were picked 
and stored in 1 ml SM with 3 % chloroform at 4°C. Rapid 
phage DNA preparation of these 122 positive plaques were
dotted (approximately 1 jig each) on a nitrocelluose filter.
Dot hybridization was performed by using a ^2p labeled DNA 
fragment corresponding to the first exon of RMPFK gene.
Eight positive clones #5, #13, #16, #31, #49, #60, #65 and 
#74 were picked up for further characterization. Approxi­
mately 200 plaques of each clone were plated on a small 
plate. The plaques were transfered to nitrocellulose 
filters in duplicates. One filter was hybridized with the 
N-terminal DNA fragment of RMPFK gene and the duplicate 
filter was hybridized with the C-terminal cDNA of RMPFK to 
confirm that the positive clones were full length RMPFK 
cDNAs. Three clones #13, #60 and #65 were chosen for the 
fourth screening to make sure that they were pure and full 
length RMPFK cDNA clones. A plaque of each clone was 
picked and stored in 1 ml SM containing 3 % chloroform at 
4°C. The pBluescript phagemid containing the RMPFK cDNA 
was excised from the Lambda ZAP II vector by using an in 
vivo excision method (Dotto et al., 1984) described in 
Appendix VI. Recombinant phagemid DNA purified by CsCl 
centrifugation was used for analysis of the insert RMPFK 
cDNA including mapping of restriction sites and sequencing.
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2.2.1.2. Endonuclease upping
Restriction enzymes Kpnl, BamHI, EcoRI, Hindlll,
SstI, Smal, PstI were used for restriction mapping of the 
cDNA clones. Digested DNA fragments of each clone were 
loaded onto a 0.8 % agarose gel in lx TBE buffer and the 
gel was run at 50 volts. After the completion of gel 
electrophoresis, the DNA fragments were transfered to two 
nitrocellulose filters by using the Southern hybridization 
method (Maniatis et al., 1982) described in Appendix VI.
The nitrocellulose filters were hybridized with both the N- 
terminal DNA probe and the C-terminal DNA probe described 
in section 2.2.1.A.
2.2.1.3. Heated Deletion, DNA eubcloning end DNA 
Sequencing
Clones #13 and #65 were chosen for nested deletion 
and DNA sequencing analyses. A sequencing primer 
complementary to the N-terminal 25 bases of RMPFK cDNA and 
the Ml3 universal primer were used for sequence analysis of 
clones #13 and #65 before performing the nested deletion 
reactions. The ExoIII and Mung bean nuclease deletion 
system (Stratagene's manual, 1989) was used to produce 
unidirectional deletions of predicable sizes of RMPFK cDNA 
clones #13 and #65 (details are described in Appendix IX). 
Briefly, the double-stranded pBluescript SK(-) phagemid DNA 
containing the RMPFK cDNA was double digested with
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restriction enzymes Kpnl and EcoRV, which are unique sites 
in this phagemid DNA. Deletion reactions were carried out 
using ExoIII and Mung bean nuclease. The deletions were 
created in the RMPFK cDNA insert but not in the vector 
pBluescript SK(-). The deleted DNA was ligated, trans­
formed into XLl-Blue cells, and plated onto LB/ampicillin 
plates. The phagemid DNA of 12 to 24 colonies was isolated 
for each deletion construct, digested with Clal or Xbal, 
and analyzed by electrophoresis on a 0.6 % agarose gel to 
screen the predicted size of the deletion product. Six 
nested deleted constructs of cDNA clone #13 and four delet­
ed constructs of clone #65 were analyzed for DNA sequence.
The DNA sequencing reactions were performed by the double- 
stranded sequencing method (Zhang et al.f 1968) described 
in Appendix X. To complete the sequencing of the full 
length RMPFK cDNA, the recombinant phagemids of clones #13 
and #65 were digested with several different restriction 
enzymes to generate the appropriate RMPFK cDNA fragments.
These partial RMPFK cDNA fragments were then subcloned into 
M13 RF as described in Appendix VIII. The single-stranded 
sequencing method was used to accomplish the sequencing of 
the full length RMPFK cDNAs.
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2.2.2. Kxpr«ssion of RMPFK in X. coli hosts
Several E. coli expression systems were tested for 
expression of recombinant RMPFK. Two of these systems are 
presented in this section.
2.2.2.1. Use of T7 rma polymsrass to direct the 
expression of cloned RMPFK
In the T7 RNA polymerase expression system, T7 RNA 
polymerase is produced in the cell from the transduced gene 
by IPTG induction (Studier et al., 1990). The host cells,
E. coli BL21(DE3), contain a lambda derivative bacterioph­
age DE3 which carries the lad gene, the lac UV5 promoter, 
the beginning of the lacZ gene, and the gene for T7 RNA 
polymerase. The promoter, lac UV5, controlling transcrip­
tion of the T7 RNA polymerase gene is inducible by IPTG.
The pET-3C vector for cloning and expression RMPFK cDNA is 
derived from the multi-copy plasmid pBR322. It carries a 
T7 promoter followed by a unique cloning site and a tran­
scription terminator,
2.2.2.1.1. Subcloning
A schematic diagram of subcloning of RMPFK cDNA into 
pET-3C is shown in Figure 8. The expression vector pET-3C 
was reconstructed by inserting a Xbal-BamHI linker contain­
ing the Shine-Dalgarno sequence and restriction sites Smal
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rigure 6. Subcloning of RMPFK cDHA Into pET-3c expression 
vector. The experimental procedure Is described In sec­
tion 2.2.2.1.1. The recombinant plasmid was used to
transform Into E, coll BL2KDE3) cells. 010: T7 promoter, 
T$: transcription terminator
and Kpnl in the region between the T7<pl0 promoter and the 
transcription terminator. The sequence of the synthetic 
linker is shown in Appendix II, RMPFK cDNA and the 
modified pET-3C vector were digested with Xbal and Kpnl. 
Fragments of interest were purified by electrophoresis on a 
0.8% low melting point agarose gel. The 3.0 Kb RMPFK cDNA 
and the pET-3C bands were cut from the gel and purified 
following the procedure described in Appendix VIII. Liga­
tion and transformation reactions were performed as de­
scribed in Appendix VIII. E. coli HMS174 strain was used 
as the host for initial cloning and analysis of recombinant 
plasmids. The 5' untranslated region and the first 140 
base pairs coding region of RMPFK cDNA were sequenced by 
using the double-stranded sequencing method in order to 
confirm that RMPFK cDNA was located at the correct position 
for expression. The recombinant plasmid pET-3C/RMPFK was 
then transformed into E. coli BL21(DE3) cells for expres­
sion.
2.2.2.1.2. Expression
BL21{DE3) cells carrying the pET-3C/RMPFK plasmid
were grown in M9 medium containing 20 |ig ampicillin/ml,
IPTG was added to the level of 1 dim when the culture
reached an AgQQ of 0.4. Cells were harvested 3 hours after
induction. Aliquots of 1 ml of the cell culture was
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collected every hour for analyzing the recombinant protein 
by SDS polyacrylamide gel electrophoresis.
2.2.2.1.3. Analysis of ths raconblnant protaln
Cloned RMPFK was analyzed by gel electrophoresis on 
8% gradient acrylamide gels. A pulse-chase experiment was 
also performed to detect the relatively small amount of 
cloned RMPFK synthesized in the B.coll cells. Typically, 1
pCi of 35S methionine was added into 50 Hi of cell culture.
The labeling was allowed to proceed for 3 minutes. The 
cells were collected by centrifugation and resuspended in 1 
x sample buffer described in Appendix V, Total cell con­
tents were analyzed by placing 40 jil of the resuspended 
cells in the sample buffer, heating 2-3 minutes in a boil­
ing water bath, and applying directly to the gel. The pro­
cedure of staining, destaining and transfer was followed as 
described in Appendix XII. Antibody against mammalian PFK 
was used for Western blotting.
2.2.2.2. The expression system driven by heat 
shock controlled laaibda pFL2 promoter 
(Ramaut, et al., 1981):
The expression vector pPL2 carries a lambda PL 
promoter which is under the control of the thermolabile 
lambda repressor (lambda cl857 repressor). The host E.
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coli strain, DF1020, is deficient in PFK (Daldal, 1983).
The cl857 plasmid encodes the thermo-sensitive mutant of 
lambda cl repressor {Remaut, et al., 1981). This cl857 
plasmid encoding the temperature sensitive mutant of Cl 
repressor was cotransformed with the recombinant pPL2 plas­
mid into DF1020 cells for expression.
A schematic diagram of subcloning of RMPFK cDNA into 
pPL2 is shown in Figure 9. A synthetic cloning linker was 
inserted into the expression vector pPL2 and the cloning 
shuttle vector pBluescript KS(+). This cloning linker 
contained the Shine-Dalgarno sequence and the unique clon­
ing sites ClaZ, XbaI, EcoRV, Kpnl and Sacl. The sequences 
of the synthetic oligonucleotides are listed in Appendix 
II. The reconstructed pBluescript KS(+) vector and 
pBluescript SK(-)/RMPFK were digested with EcoRV and Xbal.
The full length RMPFK cDNA flanked by Xbal and EcoRV sites 
was inserted into the reconstructed pBluescript KS<+) 
vector. This procedure added a Clal site and the Shing- 
Dalgarno sequence at the 5'end and a Kpnl site at the 3' 
end of RMPFK cDNA. The pBluescript KS(+)/RMPFK was trans­
formed into DH50CF' cells and plated on agar plates 
containing ampicillin. Plasmid DNA preparations of 12 
colonies were digested with SstI which is a unique site in 
RMPFK cDNA. The electrophoretic patterns of digests were 
thus used as a selection for pBluescript KS(+)/RMPFK. The
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Figure 9. Subcloning of RMPFK cDKA into the lambda pPL2 expression vector. The experimental procedure has been 
described in section 2.2.2.2. The recombinant plasmid was 
used to cotransform with cI857 into E. coli DF1020.
DNA of pBluescript KS (+)/RMPFK was then digested with Clal 
and Kpnl. This full length RMPFK cDNA insert was cloned 
into the reconstructed pPL2 which had been digested with 
Clal and Kpnl. pPL2/RMPFK was transformed into E. coll 
M5219 strain carrying a defective prophage encoding the 
cI857 thermo-sensitive repressor (Remaut, et al., 1981). 
Colonies grown on ampicillin plates were screened by direct 
double-stranded DNA sequencing of miniprepared plasmid DNA 
from 4 colonies. Postive clones were selected for 
preparation of a large quantity of pPL2/RMPFK plasmid.
The DNA of pPL2/RMPFK was cotransformed with cl857 
plasmid into E. coll DF1020 and plated onto plates 
containing ampicillin and kanamycin. These plates were 
incubated at 28°C for 30 hours. Four representative 
transformants were streaked on the selective plate (M63 
minimal media containing mannitol) and the non-selective 
plate (M63 minimal media containing glycerol). Cells con­
taining expressed RMPFK grew on the M63/mannitol plate. 
Positive colonies were streaked on plates containing ampi­
cillin and kanamycin. A single colony from each plate was 
inoculated in 2 ml 2 x YT and grown overnight. Three hun­
dred M.1 of overnight cell culture was added into 30 ml 2 x 
YT and grown to reach AgQQ « 0.7 at 28°C, heat shocked at
45°C for 30 minutes, and then allowed to grow at 42°C for 3 
hours. Twenty-five ml of cell cultures was harvested and
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sonicated in 1 ml sonication buffer. RMPFK was detected by 
SDS-PAGE and enzyme activity assay as described in Section 
2.2.4.
2.2.3. Purification of recombinant RMPFK
2.2.3.1. Growing cells and sonication
A single colony of transformed DF1020 was used to
inoculate 2 ml 2 x YT medium containing 200 jig/ml ampicil­
lin and 100 }ig/ml kanamycin. This was grown 24 hours at 
28°C in a water bath shaker. One-half ml of the 24 hour
culture was mixed with 100 ml 2 x YT containing 200 p.g/ml
ampicillin and 100 Jig/ml kanamycin. After 10 hours of in­
cubation at 28°C, a portion of this cell culture (20 ml)
was mixed with 1 liter 2 x YT containing 100 )ig/ml ampicil­
lin and 50 îg/ml kanamycin. This was incubated at 28°C 
until AgQQ = 0.95 to 1.0. To bring the liquid to 42°C rap­
idly, 500 ml 2 x YT preheated to 70°C was poured into the 
cell culture with continuous shaking, and then incubated at 
42°C for 3.5 hours.
A total of 4.5 liters of cell culture were pelleted 
by centrifugation at 4°C, 6,000 x g for 20 minutes. The 
wet cell pellet was weighed and resuspended at 15% (w/v) in 
sonication buffer (Appendix V). Cell suspension was
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transferee! to a 4 00 ml plastic beaker and sonicated (pulse, 
50%, level 6, 50%, horn tip) at 0°C for 2 minutes. This 
was repeated 5 times with 2 minutes cooling intervals. The 
crude cell lysate was spun at 4°C for 1 hour at 12000 x g 
for 1 hour. The supernatant was saved and the cell pellet 
was resuspended in 30 ml sonication buffer and sonicated as 
described above 3 additional times.
2.2.3.2. Ammonium sulfate precipitation
Powdered (NH^^SO^ was slowly added into the crude
extract up to 35% saturation. This was gently stirred in 
an ice water bath for 1 hour. The milky suspension was 
centrifuged for 30 minutes at 12,000 x g, 4°C. Powdered
(NH^^SO^ was slowly added into the clear supernatant to
55% saturation, cooled in an ice water bath for 2 to 4 
hours, and centrifuged for 1 hour at 12,000 x g, 4°C. The 
pellet was resuspended in 20 ml of column buffer as 
described in Appendix V. This protein solution was dia- 
lyzed against 4 liters of column buffer overnight with 2 
changes. Aliquots were saved for the PFK activity assay, 
protein concentration assay and SDS-PAGE analysis.
2.2.3.3. Cibacron blue F3GA agarose column
Cibacron Blue F3GA Agarose (100 ml) was suspended in 
column buffer. The resin was transferred to a Bio-Rad
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column <30 x 2.5 cm) without trapping air bubbles. The 
resin was equilibrated with column buffer at 4°C, at a flow 
rate of 1 ml/min for overnight. The conductivity of the 
equilibrated buffer and the eluate were compared to 
determine whether the resin was equilibrated. The protein 
sample was loaded onto the column and washed with column 
buffer until the eluate at 280 nm was almost zero. The 
column buffer containing 5 mM Fru 6-P and 5 mM ATP was used 
to elute RMPFK. Three-ml fractions were collected and PFK 
activity was determined using the pH 8.0 assay conditions 
described below. The fractions which contained the 
majority of PFK activity were combined, dialyzed against 2 
liters of column buffer, and concentrated in an Amicon 
ultrafiltration cell.
2.2.3.4. D U E  cellulose (DC 52) coluan
DEAE cellulose (DE 52) <5 g) was suspended in 250 ml
of 0.5 N NaOH for 30 minutes, and washed with H20 until the
pH reached about 9. This was repeated one more time. The 
resin was then washed with 0.5 N HC1 for 30 minutes and
rinsed with H20 until pH * 6.0. Column buffer <50 mM Tris-
phosphate, 25 mM NaF, 0.1 mM EDTA, 0.1 mM ATP, 10 mM DTT
and 0,1 mM PMSF) was added to the resin and soaked over­
night with 3 changes until the pH of the resin reached
8.0. Then, the resin was packed into a column <10 x 1.5
cm) and equilibrated with 300 ml column buffer overnight.
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The protein sample was loaded onto the column and washed 
with 500 ml column buffer. A stepwise elution was used to 
elute PFK activity. Column buffer containing 0.2 M Tris- 
phosphate eluted the majority of PFK activity. Fractions 
of 0.8 ml were collected and combined. PFK activity was 
determined using the pH 8.0 assay condition described 
below. The fraction containing PFK activity was dialyzed 
and concentrated in a Centricon-30 tube. The purity of the 
collected PFK protein was determined using 8% SDS-PAGE.
2.2.4 Assays of PIT activity (To* t Kanp, 1982)
RMPFK was dialyzed against one liter of dialysis 
buffer for 24 hours at 4°C. Two types of dialysis buffer 
were used. RMPFK in dialysis buffer I (50 mM Tris, 1 mM 
DTT, 0.1 mM EDTA, 0.1 mM ATP, pH 8.0) was used for checking 
enzyme activity, and RMPFK in dialysis buffer II (50 mM 
TES, 1 mM DTT, 0.1 mM EDTA, 0.1 mM ATP, pH 7.0) was used 
for allosteric kinetic studies. The enzyme solution was 
diluted with dilution buffer (50 mM TES, 1 mM DTT, 0.1 mM 
EDTA, pH 7.0) prior to assay of PFK for determining 
allosteric properties. The actual concentrations of ATP 
and AMP were determined spectrometrically at pH 7.0.
Auxiliary enzymes were mixed (4 mg aldolase, 2.4 mg 
glycerol 3-phosphate dehydrogenase and 0.2 mg triose 
phosphate isomerase) and dialyzed against 1 liter of 50 mM
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Tris-Cl (pH 8.0) or 50 mM TES (pH 7.0) at 4°C for 16 hours 
with two changes of buffer.
PFK activity was measured by an assay coupled to NADH 
oxidation as described by Foe and Kemp (1982) . For 
determination of enzyme activity, PFK was assayed at pH
8.0. The reaction mixture contained 50 mM Tris-Cl pH 8.0,
5 mM MgCl2, 1 mM EDTA, ImM DTT, 0.2 mM NADH, ImM ATP, ImM
Fru 6-P, and the following quantities of auxiliary
enzymes: aldolase, 40)ig/ml; glycerolphosphate dehydrogenase,
24 jig/ml; triose phosphate isomerase, 2 jig/ml. For deter­
mination of allosteric regulatory properties of PFK, the 
enzyme was assayed at pH 7.0. The reaction mixture con­
tained 50 mM sodium/TES pH 7.0, 150 mM KC1, 5 mM MgCl2, 1
mM EDTA, ImM DTT, and 0.2 mM NADH. The NADH oxidation was 
monitored at 340 nm using the Gilford Response II spectro­
photometer at 25°C. One unit of activity was defined as
the amount that catalyzed the conversion of one jimole of
Fru 6-P to Fru 1,6-P2 per minute (Kemp, 1975).
A. An example of the standard assay condition for 
checking the maximum RMPFK activity is shown as follows: 
Reaction mixture for 100 assays:
Stock solution Volume (ml)
1 M Tris-Cl (pH 8.0) 5.0
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1 M MgCl2 0.5
1 M DTT 0.1
0.5 M EDTA 0.2
20 mM NADH 1.0
H20 to 96 ml
This reaction mixture was kept at 25°C during the assay and 
a 0.96 ml aliquot was used per assay.
Each assay contained:
Reagent Volume (ill)
Auxiliary enzymes 10
0.1 M Fru 6-P 10
0.1 M ATP 10
PFK (diluted) 10
The amount of PFK used was within the linear rate range.
The reaction was initiated by adding Fru 6-P.
B. An example of the assay condition for checking the 
allosteric regulatory properties of RMPFK is shown as 
follows:
Reaction mixture for 100 assays:
Stock solution Volume (ml)
1 M TES (pH 7.0) 5.0
1 M MgCl2 0.5
1 M KC1 15.0
1 M DTT 0.1
0.5 M EDTA 0.2
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20 mM NADH 1.0
H2O to 94 ml
On the day of the experiment, a stock solution was made 
that contained all the reagents except ATP, PFK, auxiliary 
enzymes and Fru 6-P. These were added to reaction mix 
(0.96 ml) in the following order: 1) ATP, 2) PFK, 3) 
auxiliary enzymes, 4) Fru-6-P, with a pause of 4 minutes at
25°C prior to the addition of Fru 6-P. MgCl2 was always
present with 3 mM higher concentration than ATP. Inhibi­
tors citrate, PEP or creatine phosphate were always added 
after the addition of ATP. Rates were determined for 2 to 
4 minutes after the addition of Fru 6-P.
2.2.5 Calculation of kinatic results
Nonlinear regression analysis of experimental data 
was performed by using the program InPlot™ (Version 4.0,
1992) with an IBM-PC computer; saturation kinetics for 
variation of [Fru 6-P] were determined using the equation 
for the MWC model, the Hill equation, or the rectangular 
hyperbolic equation.
2.2.6 Protein assay
Protein determination was performed by using 
Coomassie brilliant blue dye-binding assay solution provid­
ed by Bio-Rad. Bio-Rad protein assay solution was diluted
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by distilled water in a 1:5 (v/v) ratio. The assay 
standards were made using known concentrations of bovine
serum albumin at 1, 5, 10, 15 and 20 |ig/100 ill. One hun­
dred ill of each standard was added to 5 ml diluted assay 
solution. The absorbance of each standard (1 ml) at 595 nm 
was recorded to create a standard curve using the spectro­
photometer Gilford Response II. The unknown protein 
concentration was determined by comparing the absorbance of 
several dilutions of the unknown protein to those of the 
standard curve.
2.2.7 Site-directed mutagenesis
Four mutations Q200A (Gln-200 to Ala), Q200E (Gln-200 
to Glu), Q200N (Gln-200 to Asn), Q200R (Gln-200 to Arg)were 
constructed by using the "Altered Sites in vitro 
Mutagenesis" kit purchased from Promega Biotec Corp (Madi­
son, Wl). A schematic diagram of the "Altered Sites in 
vitro Mutagenesis" procedure is shown in Figure 10. The 
details of the procedure is described in Appendix XIII.
Briefly, the system employes a phagemid vector, pSELECT-1, 
which contains two genes for antibiotic resistance. One of 
these genes, for tetracycline resistance, is always func­
tional. The other, for ampicillin resistance, has been 
inactivated by an amber codon at a PstI site. A partial 
RMPFK cDNA fragment containing the sequence encoding for
mutagenic 
oligo
pSELBCT-l/mm 
Amp*
pSELECT-1/RMPFK
BMPA/r
Amp
1. Anneal ampictllin repair 
oligo and mutagenic oiigo.
2. Synthesize mutant strand 
with T4 DMA polymerase 
and ligate.
Transform BMH 71 -18 
mut S. Grow in media 
ampidlUn.
Prepare mini-prep DNA.
S. Transform JM1Q9. Select 
mutants on ampidilin plates.
Screen for mutants by 
direct sequencing.
Figure 10. Schematic diagram of the "Altered Sitea la 
vitro Mutagenesis*. The smtagenesis vector pSELECT-1 m s  purchased from Pronega Biotec Corporation (Madison, MI) .
A partial cDNA fragment of RMPFK was subcloned into the 
polylinlcer region of pSELECT-1 plasmid. The procedure for 
mutagenesis is described in Appendix XIII.
Gln-200 was subcloned into the polylinker region of 
pSELECT-1 plasmid between the EcoRI and BamHI sites. An 
oligonucleotide is provided which restores the ampicillin 
resistance to the mutant strand during the mutagenesis 
reaction. This oligonucleotide is annealed to the single­
stranded DNA template at the same time as the mutagenic 
oligonucleotide (containing the sequence for mutation of 
Gln-200 of RMPFK). Subsequent synthesis and ligation of 
the mutant link the two oligonucleotides. The DNA is 
transformed into a repair minus strain of E. coli (BMH 71- 
18 mut S) and the cells are grown in the presence of 
ampicillin, yielding large numbers of colonies. Plasmid 
DNA isolated from each colony is transformed into E. coli 
JM109 cells to ensure proper segregation of mutant and wild 
type plasmids.
Plasmid DNA was prepared from colonies randomly 
picked from the transformation plates and selected for cor­
rect mutation by sequencing reaction using a single dideox- 
ynucleotide triphosphate. The correctly mutagenized RMPFK 
cDNA fragment was excised by digestion with XbaX and BamHI. 
This fragment was then religated Into the pPL2/RMPFK plas­
mid at correct position. The recombinant plasmid contain­
ing the mutagenized RMPFK cDNA was transformed into E. coli 
DF1020 cells for expression. Purification and assay of mu­
tagenized RMPFK were performed as those described for wild 
type recombinant RMPFK.
CHAPTER THREE 
RESULTS 
3.1 Purification and Characterisation of ru11-length 
RMPFK cDNAs
3.1.1 DNA screening of rabbit nuacle PFK CDNA 
library
Lambda ZAPII phage plaques containing rabbit muscle 
cDNA inserts were screened for the PFK cDNA using a 
nicked-translated DNA fragment containing the 3' region of 
RMPFK cDNA as hybridization probe. Totally 122 plaques 
gave the reproducible signals on duplicate filters from 
the first screening. Figure 11 shows the positive signals 
on one of the 20 filters and the duplicate. Rapid phage 
DNA extracted from these 122 plaques were further screened 
with an end-labeled DNA fragment containing the 5' region 
of RMPFK gene (corresponding to exon I of the gene) by dot 
blot hybridization (Figure 12). Eight plaques were fur­
ther purified by replating twice.
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figure 11. Purification of rabbit muscla PFK cDNA cloned
in lambda ZAPII phage DMA. XLl-Blue cells CIO®) were In-£fected with the phage particles (10w) and plated onto 20 
NZY agarose plates (150 mm). Nitrocellulose filters (132 
mm diameter BA85, Schleicher 6 Schuell) in duplicate were 
lifted from each plate and hybridized with nick-translated 
3' fragment of RMPFK cDNA. Positive plaques that were 
shorn to be present duplicate filters were further screened 
by dot hybridization.
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Figuzt 12. Nitrocellulose dot blot hybridisation of full length RMPFK cDNAs. Lambda ZAPII phage DNA that was 
purified from every positive plaque (Figure 11) was dotted 
onto a nitrocellulose filter and hybridized with an end la­
beled DNA fragment corresponding to exon I of RMPFK gene. 
The big spot on the top of this figure is the positive 
control (containing probe DNA).
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3.1.2. Endonuclease upping of RMPFK CDNA clones
Phagemid DNA excised from three purified phage 
clones #13, #60 and #65 was characterized by digesting 
with several restriction enzymes followed by Southern blot 
hybridization using an end-labeled DNA fragment corre­
sponding to the first exon of RMPFK gene (Figure 13B, 14B 
and 15B) or a nick-translated DNA fragment containing the 
3' region of RMPFK cDNA mentioned above (Figure 13C, 14C 
and 15C) as probes. The restriction maps are shown in 
Figure 16A, 16B and 16C. Clones #60 and #65 have identi­
cal restriction maps. However, the restriction map of #13 
is different from that of #60 and #65 in the 5' region. A 
sequencing primer complementary to a portion of the first 
exon of RMPFK gene was used to sequence clones #13, #60 
and #65. Results of DNA sequence analysis showed that 
clones #60 and #65 have a identical sequence in the 5'-un­
translated region, but clone #13 has a different sequence 
from that of clone #60 and #65 in this region. Therefore, 
clones #13 and #65 were chosen for further characteriza­
tion.
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Figure 13. Nitrocellulose blot hybridization of RMPFK cDNA fragment* from clona #13. Purified pBluescriptSK (-) 
phagemid DNA containing RMPFK cDNA insert was digested 
with BamHI (B), Hindlll (H), EcoRI (E), Kpnl (K), Smal 
(Sm), SstI (St) and PstI (P) singly or in combination. 
Fragments produced were separated by electrophoresis on an 
0.8% agarose gel (A), blotted onto nitrocellulose filters 
and hybridized with an end-labeled DNA fragment corre­
sponding to exon I of RMPFK gene (B) or blotted with a 
nick-translated DNA fragment containing the 3' region of 
RMPFK cDNA (C). The size marker (M) was Hindi11-digested 
lambda phage DNA. S: Intact pBluescriptSK(-)/RMPFK 
plasmid DNA.
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Figure 14. Nitrocellulose blot hybrid! zmtion of RMPFK 
cDNA fragments from cion* #60. For an explanation of the 
method used see Figure 13.
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Figure 15. Nitrocellulose blot hybridization of RMPFK cDMA fragments from clone #65. For an explanation of the 
method used see Figure 13.
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Figura 16. Raatriction naps of tha full-langth RMPFK cDNA #13 (A), #60 (B) and #65 (C). Xbal (X), BamHI (B),
HindiII (H), EcoRI (E), Kpnl <K), Smal (Sm), SstI (St),
PstI (P), and AccI (A).
3 . 1 . 3  Characterisation of full length RMFnt cDNAs
Phagemid DNA containing the full length RMPFK cDNA 
of clones #13 and #65 was serially deleted using the 
ExolII/Mung bean nuclease deletion method. Double-strand­
ed or single-stranded DNA from six deletion constructs of 
clone #13 (Figure 17A) and four deletion constructs of 
clone #65 (Figure 17B) were purified and used as templates 
for DNA sequence analysis. The primers used in these 
analyses were universal primer and synthetic oligonucle­
otides corresponding to or complementary to some codons of 
RMPFK. The sequence analyses were accomplished by sub­
cloning several partial cDNA fragments of both clones into 
M13 for single-stranded sequencing. A schematic diagram 
of the sequence analyses is shown in Figure 18. Total se­
quence of approximately 3000 bp in the coding region, 5' 
untranslated region and 3' untranslated region of both 
RMPFK cDNAs have been determined. The sequence alignment 
of these two cDNAs in the coding region and the 3' un­
translated region is shown in Appendix I. The result 
shows that the entire coding sequence including 11 bp up­
stream of ATG codon and the 3' untranslated region of 
these two cDNAs are identical. The sequence alignment of 
the 5' untranslated regions of these two cDNAs shows the 
sequence diversity in this region (Figure 19). A surpris­
ing feature in cDNA-A (#65) is the existence of a TATAAAA 
sequence in the transcript of the RMPFK gene. This fea­
ture will be discussed in Section 4.1.
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Figure 17. Nested deletions of full-length FMFFK cDNAs
Purified pBluescript SK(-) phagemid DNA containing deleted 
RMPFK cDNA insert was analyzed by electrophoresis on an 0.8 
% agarose gel. Six nested deletion products of cDNA 113 
are shown in (A) and four nested deletion products of cDNA 
#65 are shown in (B). The size marker was Hindlll-digested 
lambda phage DNA or 1 Kb DNA ladder. Purified pBluescript 
SK(-) phagemid DNA containing full-length RMPFK cDNA is 
shown in lane 1 of both (A) and (B).
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rigura 18. Saquancing stratagias used to saquanca full- langth RHPFK CDNA 13 (A) and cDMA 65 <B). Top line, scale 
In Kb; arrows, fragments subcloned in M13mpl8 or mpl9 phage 
vectors, or deletion constructs (described in Figure 17}. 
The directions of sequencing are indicated by arrow heads.
cDNA-A CTCTCCGGAG GTATAAAACG TGAGAGGGGC AGGCTGCTGA CCCCCAATCT
cDNA-A AGTCCAAACC CTTCTTAGTG CATAAGAAGC TGTTCAAGTC CCACACAAGG
cDNA-B TGTCC TAACTGACCA TCGTCTTGCC
cDNA-A TATTAGAGTG GATC ATG ACC CAT GAA___
cDNA-B TTCTAGAGTG GATC ATG ACC CAT GAA___
M T a c ___
Figure 19. Sequence diversity in ths 5'-untranslated re­gion of rabbit aiuscle PIT cDNA. Bold prints indicate 
identical sequences. Plain prints are diverse sequence. 
"TATA" box is underlined. Coding sequences downstream of 
ATG codon are identical in cDNA-A (corresponding to cDNA 
65) and cDNA-B (corresponding to cDNA 13) (for sequence 
comparison of the coding region and the 3' untranslated re­
gion of both cDNAs see Appendix I).
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3.2. Expression of Rabbit Muscle PrK in t. coli
3.2.1. Expression of RMPFK
Two types of expression systems have been used in 
this study. The first system is under the control of T7 
promoter, whereas the second one is driven by the lambda 
pPL2 promoter. SDS-PAGE and Western blot analysis show 
that the transformation of E. coli BL21(DE3) with pET- 
3c/RMPFK expresses RMPFK after IPTG induction (̂Figure 20). 
RMPFK produced in E. coli BL21(DE3) is the same size as 
the authentic protein which is 85 KDa.
The transformation of E, coli DF1020 with pPL2/RMPFK 
and pCI857 and subsequent plating on selective plate 
M63/mannitol shows that cloned RMPFK has been expressed in 
E. coli DF1020 (region II, IV, V in plate A) (Figure 21). 
SDA-PAGE shows a significant level of RMPFK expression 
(Figure 22). In addition, the pFL2/DF1020 expression has 
an advantage of providing a visible selection for clones 
which express RMPFK. This system has been used throughout 
this work for the expression of wild type and mutant 
RMPFK.
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i
rigure 20. itastern blot of recombinant RMPFK protein.
Lane 1: pure RMPFK from Sigma; lane 2: E. coli 
BL21(DE3), not transformed; lane 3: E. coli BL21(DE3), 
transformed with pET-3c vector; lane 4: E. coli BL21(DE3), 
transformed with pET-3c/RMPFK, uninduced; lane 5-7: E. coli 
BL21(DE3), transformed with pET-3c/RMPFK, IPTG induced, and 
further grown for lhr (5), 2 hrs (6), and 3 hrs (7). Posi­
tion of recombinant RMPFK is indicated by an arrow. The 
other bands are E. coli proteins that cross-link with rat 
anti-PFK antibody.
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Figure 21. Selective plat* demonstrating tha expressionof elonad RMPFK in E. coli DF1020. Plate (A): M63 minimal 
media containing mannitol, Plate (B) : M63 minimal media 
containing glycerol; I: E, co2i DF1020, not transformed; 
II, III, IV, V: pPL2/RMPFK and pCI857 cotransformed into 
DF1020; VI: pPL2 and pCl857 cotransformed into DF1020.
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Figure 22. SDS-PAGE analysis on tba axprasslon ofracoeibinant RMPFK in X. coil DF1020. The samples are pre­
pared directly from crude extracts of E. coll cells. Lane 
1: E. coll DF1020, transformed with pPL2/RMPFK, uninduced; 
lane 2-5; E, coll DF1020, transformed with pPL2/RMPFK, 
induced by heat shock, and further grown for lhr (2), 2 hrs 
(3), 3 hrs (4), 4 hrs (5), and ; lane 6: RMPFK from Sigma; 
lane 7: E. coll DF1020, transformed with pPL2 vector; Lane 
8: E. coll DF1020 not transformed; M * Size Markers (Bio- 
Rad) . All transformations were carried out by co-transfor­
mation with pCX857. Position of recombinant RMPFK is indi­
cated by an arrow. The density of some other protein bands 
also increased during induction. These proteins may be E. 
coll heat shock proteins.
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3.2.2. Purification of RMPFK from X. aoll DF1020
The purification procedure has been described in 
Section 2.2.3. It includes ammonium sulfate 
precipitation, and chromatography using an affinity column 
(Cibacron Blue F3GA-agarose) and an ion exchange column 
(DEAE cellulose). The results of wild-type RMPFK purifi­
cation are shown in Figure 23 and Table 4.
The result of SDS-PAGE shows that wild-type RMPFK 
has been purified. Approximately 1000-fold purification 
is achieved during the purification of RMPFK from B. coll
DF1020 (Table 4). The recovery is 710 ng of purified 
RMPFK from 4.5 liters of E. coli culture. This scale is 
suitable for the enzymological studies reported here.
3.2.3. Comparison of the cloned and the authentic 
RMPFK
SDS-PAGE shows that the cloned RMPFK has the same 
molecular weight as that of authentic RMPFK (Figure 22 and 
23). Enzyme kinetic studies prove that they have the same 
kinetic values with respect to Fru 6-P and ATP 
concentration (Table 5) at pH 7.0 and pH 8.0. The specif­
ic activity of the recombinant RMPFK is slightly lower 
than the reported value. Although the DEAE cellulose pu­
rified enzyme showed to be a single band on SDS-PAGE, the 
preparation may contain some inactive PFK protein. The 
inactive PFK protein has the same chromatographic and
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Tigura 23. SDS-PAOE analysis of the purification of raconbinant BMPFK.
Lane 1: RMPFK from Sigma Chemical Co. 
lane 2: crude extract
lane 3: ammonium sulfate fraction (35 % to 55 % sat'n) 
lane 4: after Cibacron blue F3GA column 
lane 5: after DEAE cellulose column 
M: size markers
Table 4.
Purification of racoobinant RMFTK from X. coll DP1020
Step Total
volume
ml
Total
Protein
mg
Total
Activity
U
Specific
Activity
U/mg
Recovery
%
Crude
extract
135 2200 283 0.13 100
Ammonium
sulfate
26 450 241 0.52 89
Cibacron
F3GA
12 6.6 173 26 61
DEAE 0.94 0.71 126 180 49
* One unit of activity is defined as a change in absor­
bance at 340 nm of 12.4 per min (Kemp, 1982). Protein 
concentrations were determined as described in Section 
2.2.6.
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Table 5.
(A) Comparison of the kinetic parameters between 
commercial RMPFK and recombinant RMPFK at pH 8.0.
Enzyme Form Specific Activity Km (app) Km (app)
(units/mg) Fru 6-P (mM) ATP (mM)
RMPFK 220* 0.21 ±  0.041 0.09 ±  0.013
(from Sigma)
RMPFK 180 0.18 ±  0.043 0.10 ±  0.021
(cloned)
Enzymes were assayed as described in Section 2.2.2.4. 
The Km (app) was determined by using the Rectangular 
hyperbolic equation (Y * A*X/B+X; A=Vmax, B*Km). The Km 
(app) for Fru 6-P was determined by measuring enzyme ac­
tivity while varying Fru-6-P concentration from 0.05 mM to 
2 mM with a constant ATP concentration of 1 mM. The Km 
(app) for ATP was determined by measuring enzyme activity 
while varying ATP concentration from 0.1 mM to 2 mM with a 
saturating Fru 6-P concentration of 1 mM. The value of 
the Km is presented with a standard error value.
♦Data from product profile of RMPFK purchased from Sigma.
(B) Comparison of the kinetic parameters between 
commercial RMPFK and recombinant RMPFK at pH 7.0.
Enzyme Form Specific Activity Km (app) 
(units/mg) Fru 6-P (mM)
RMPFK 170 0.40 ±  0.042
(from Sigma)
RMPFK 140 0.46 +. 0.073
(cloned)
The Km (app) was determined from the Hill plot ( a 
double logarithmic plot of log(v/l-v) vs. log[SJ) using
the program Inplot™ on an IBM PC. The Km (app) for Fru- 
6-P was determined by measuring enzyme activity while 
varying Fru-6-P concentration from 0.05 mM to 2 mM with a 
constant ATP concentration of 1 mM. The value of the Km 
is presented with a standard error value.
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electrophoretic mobility as the active protein. The wash­
ing buffer containing NAD and ADP may remove the inactive 
PFK protein during chromatography of the enzyme using Ci­
bacron F3GA agarose (Dunaway, personal communication),
The elution buffer containing Fru 6-P, ATP and EDTA would 
recover PFK with high specific activity.
3.3. Mutation of Gln-200 to Alanine, to Arginine, to 
Asparagine and to Glutamate
3.3.1. Mutation and the expression of mutants
Site-specific mutants of cloned RMPFK are 
constructed for the purpose of investigating the alloster- 
ic properties of this enzyme. The following point muta­
tions are introduced by using the Promega in vitro mu­
tagenesis kit (Figure 10): Gln-200 (CAG) to Ala (GCG) 
(Q200A), Arg (CGG) (Q200R), Asn (AAT) (Q200N) and Glu 
(GAG) (Q200E). The mutants are identified by sequencing 
randomly selected colonies after the mutagenesis reactions 
(Figure 24). The nucleotide sequences of these mutant 
codons are shown in Figure 25.
The results of selective plating on M63/mannitol 
show that mutants Q200A, Q200R and Q200E are expressed in 
£. coli DF1020. However, expression of Q200N is not de­
tected on the selective plate (Figure 26). The reason for 
this failure in not clear. Three mutants Q200A, Q200R and 
Q200E have been purified (Figure 27).
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Figure 24. Method of screening for mutants.
Track sequencing was used to identify mutants. Sequenc­
ing primer PFK 3 (Appendix 1) was used as a primer to 
perform a ddA or a ddC sequencing reaction on wild-type 
(lane 1, A 4 B), and mutants (lane 2-6, A) (lane 2-5, B) 
and these were loaded on a 6% sequencing gel. The arrow 
shows the mutants identified.
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Q200RQ300A
A G C T
T ' 
A 
A ■
Q200N
A 0 C T
Q200K
Figure 25. ONA sequence showing ths nutations of Gln-200.
In vitro mutation was carried out using a Promega 
"Altered Sites in vitro mutagenesis" kit. The method is 
described in Appendix XIII. Sequencing was performed by 
the dideoxy chain termination method using a "Sequenase" 
(USB) kit as described in Appendix IX. WT, wild type.
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Figure 26. Salactiva plat* damonst rating th* expressionof mutants of RMPFK in E.coli DF1020. Plate (A) : M63 
minimal media containing mannitol; Plate (B): M63 minimal 
media containing glycerol; I. E. coli DF1020; II. E. coli 
DF1020, transformed with pPL2 vector and pCI857 plasmid; 
III. E. coli DF1020, transformed with wild type 
pPL2/RMPFK; IV, V, VI, VII: E. coli DF1020, transformed 
with mutated pPL2/RMPFK and pCl857, Q200A (IV), Q200R (V), 
Q200N (VI), and Q200E (VII).

97,400
66,200
31 ,0 0 0  • *
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Figure 27. SD8-FAGE showing ths purification of mutants 
O f  RMPFK.
Lane X: RMPFK from Sigma Chemical Co.
Lane 2: crude extract of wild type RMPFK
Lane 3: ammonium sulfate fraction (35% to 55%) of wild type
RMPFK
Lane 4: wild type RMPFK,
Lane 5: wild type RMPFK,
cellulose column 
Lane 6: pure Q200A RMPFK
Lane 7: pure Q200R RMPFK
Lane 8: pure Q200E RMPFK
M : size markers
after Cibacron blue F3GA column 
after DEAE
3.3.2. Comparison of the kinetics of wild typa 
FMPTX and the thraa mutants
The recombinant RMPFK and its three mutants, Q200A, 
Q200R and Q200E, have different kinetic parameters with 
respect to both substrates at pH 7.0 as well as at pH 8.0
(Table 6). At pH 8.0, the mutant Q200E is
about 14-fold higher than that of wild type. Under these
conditions, the mutant Q200A has a 15-fold higher Km^TP)
than wild type (Table 6A). These results indicate that 
different mutations at position 200 affect the affinities 
of RMPFK for each of the two substrates to different 
extents at pH 8.0. At this pH, inhibition by ATP and co- 
operativity of Fru-6-P binding are not present.
At pH 7.0, the effects caused by these mutations are 
dramatic. First of all, the wild type RMPFK and the three 
mutants, uninhibited by ATP at pH 8.0, are now subject to 
ATP inhibition. When activity is measured against ATP 
concentration, the activity of the wild type enzyme 
increase rapidly, then starts to drop at 0.6 mM ATP. On 
the other hand, the activity of the Q200R mutant keeps in­
creasing up to 7 mM ATP. The effect of ATP concentration 
on the Q200E mutant can only be observed at 50 mM Fru 6-P 
(Figure 28), and the activity of the Q200A mutant is too 
low at pH 7.0 for proper analysis. The conditions neces­
sary for investigating the cooperative binding of Fru 6-P
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Table 6.
(A) Effect of Gln-200 mutation on the kinetic parameters 
of RMPFK at pH 8.0.
Enzyme Form Specific Activity Km (app) Km (app)
(units/mg) Fru 6 - P  (mM) ATP (mM)
wild Type 
(cloned)
180 0.18 ±  0.042 0.10 ± 0.025
Q200R 110 0.22 ±  0.021 0.47 ± 0.030
Q200E 44 2.5 ±  0.53 0.49 ±  0.061
Q200A 140 0.42 ±  0.038 1.3 ± 0.17
The Km (app) was determined as described in Table 5A.
The Km (app) for Fru 6-P was determined by measuring en­
zyme activity while varying Fru 6-P concentration with a 
optimal ATP concentration (1 mM for wild type, 4 mM for 
Q200A and Q200R, and 2 mM for Q200E). The Km (app) for 
ATP was determined by measuring enzyme activity while 
varying ATP concentration with a saturating Fru 6-P 
concentration (2 mM for wild type, Q200R and Q200A; 10 mM 
for Q200E). The value of the Km is presented with stan­
dard error.
<B) Effect of Gln-200 mutation on the kinetic parameters 
of RMPFK at pH 7.0.
Enzyme Form Specific Activity Km (app) Hill #
(units/mg) Fru 6-P (mM) n
Wild Type 
(cloned)
150 2.00 ±  0.061 2.4 ±  0.43
Q200R 85 0.51 ±  0.025 1.9 ±  0.22
Q200E 16 28 ± 1.7 1.0 ±  0.40
Q200A N.D. N.D. N.D.
The Km (app) for Fru-6-P and the Hill coefficient n 
were determined from a Hill plot as described in Table 5B. 
The Km (app) for Fru 6-P was determined by measuring en­
zyme activity while varying Fru 6-P with a constant ATP 
concentration of 7 mM. The units of wild type, Q200A, 
Q200R and Q200E were adjusted to the same level at pH 8.0 
as described by Foe and Kemp (1982). The determinations 
were made at optimal concentrations of Fru-6-P and ATP for 
all PFKs at pH 8.0. Activity of each enzyme at pH 7.0 was 
also measured as described by Foe and Kemp (1982).
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Figure 28. Effecta of ATP concentrations on the activityof the wild type RMPFK and its mutants. wild type ( •), 
Q200R (a), Q200E (□) Q200A (A)/ Relative activity is 
based on the maximum activity of the enzyme in the pres­
ence of saturating concentrations of Fru-6-P and ATP at pH 
8.0 as listed in Table 6A. The effect of ATP concentra­
tion on the enzyme was determined with a constant Fru 6-P 
concentration of ImM (for wild type and Q200R mutant), or 
50 mM (for Q200B and Q200A mutants) at pH 7.0.
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, ie., pH 7.0 and 7 mM ATP, were chosen based on these 
results. Because an ATP concentration of 7 mM is required 
for maximum activity of the Q200R mutant, all studies for 
which Km (app) and the Hill coefficient for the wild type 
enzyme and the three mutants are compared use an ATP con­
centration of 7 mM. Under these conditions (Table 6B,
Figures 29 A, B), RMPFK is initially in the T conforma­
tion; thus it binds Fru-6-P cooperatively and responds to
the concentrations of the effectors (Fru 2,6-P2 or
citrate) (Figures 30, 31, 32, 33).
The data in Table 6B summarizes the behavior of the 
wild type enzyme and the three mutants. The data have 
been obtained from the sigmoidal saturation curve (rela­
tive activity vs. Fru 6-P concentration) of each enzyme.
The half saturation concentration, Km (app), and the Hill 
coefficients were both ultimately derived from the sigmoi­
dal saturation curves. Both the Km (app)(Fru 6-P) and the 
Hill coefficient were determined directly from the Hill 
plot. The Km (app) for Fru 6-P of the Q200R mutant is 4- 
fold lower than that of the wild type enzyme, while the Km 
(app) for Fru 6-P of Q200E mutant is 14-fold higher than 
that of the wild type enzyme. The activity of the Q200A 
mutant is too low at pH 7.0 to allow accurate analysis of 
the effect of Fru-6-P concentration. The value of the 
Hill coefficients for the enzymes vary from n - 2.4 i  0.43 
(for wild type enzyme) to n * 1.9 +. 0.22 (for Q200R
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mutant) and n - 1.0 +. 0.40 (for Q200E mutant) (Table 6B) .
A Hill coefficient of 2.8 ±. 0.32 has been determined for 
the wild type enzyme at pH 7.0 in the presence of 1 mM 
ATP. This value is comparable to the value of 3.0 ob­
tained by Valaitis et al. (1987) for RMPFK Isolated from 
rabbit skeletal muscle. Recall that an ATP concentration 
of 7 mM was necessary for the above comparison because of 
the nature of the ATP saturation of Q200R. Q200A mutant
is essentially inactive under the same conditions. This 
mutant cannot achieve half-saturation, even with a concen­
tration of Fru-6-P over 200 mM, in the absence of Fru-2,6-
P2- The Fru-6-P saturation curves of the wild type enzyme
and the three mutants are shown in Figure 29.
The effects of the activator and inhibitor on the 
wild type enzyme and the three mutants are demonstrated 
from the results of the Fru 6-P saturation curves (Figure
30, 31, 32 and 33). After activation by Fru 2,6-P2, the
kinetic data of each enzyme fits to the rectangular 
hyperbolic equation much better than before such activa­
tion (Table 7). The justification of the curve-fitting to 
the kinetic data will be discussed in Section 3.3.3.
The value found for the Hill coefficient decreases (n - 
1.4 ±  0.85 for WT; 1.1 + 0.17 for Q200R; 1.2 ±  0.27 for
Q200E, and 1.1 ±. 0.42 for Q200A) upon Fru 2,6-P2 activa­
tion even in the presence of 7 mM ATP. Therefore, ATP
Figure 29. Comparison of the offset of [Fru 6-P] on the activity of the wild typa RMPFK and its mutants; Q200R, Q200A and Q200E. (A) wild type (•), Q200R (&), Q200E
( □) Q20QA (A >; The conditions of these experiments are 
described in Section 2.2.4 (Foe and Kemp 1982). The as- 
says were performed at pH 7.0 in the presence of 7 mM ATP. 
Relative activity is based on the maximum activity of the 
enzyme in the presence of saturating concentrations of 
Fru-6-P and ATP at pH 8.0 as listed in Table 6A. (B) Ten
fold higher concentration of Fru-6-P than that in (A). 
Q200E ( □ ) Q200A (A ) .
The equation for the MWC model (equation I, for de­
scribing the cooperative saturating curves) that was used
by Inplot™ is (Y « C* [ (X/A) * (1+ (X/A) ) 3] / [ (1+ (X/A) ) 4+B], A 
* KR, B - L, equilibrium constant for the T * R
interconversion, C - Vmax) The rectangular hyperbolic
equation (equation II) that was used by Inplot™ is (Y * 
A*X/(B+X); A ■ Vmax, B - Km). These equations were used 
for curve fitting to the kinetic data of each enzyme. The 
evaluation of goodness-of-fit of these two equations 
fitted to the same data is presented by comparing the sum- 
of-squares value calculated.
The sum-of-squares values of these two types of 
curve fitting (I/II) are shown as follows: 
wild type (0.0019/0.11), Q200R (0.040/0.17), Q200E 
(0.0044/0.0091). The curves were drawn using the equation 
based on the MWC model. Since the Q200A mutant is 
essentially inactive, the linear regression program was 
used to draw the line.
The values of the parameters used in both equations 
are listed in Table 7.
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Figure 30. Effects of Fru-2,6-^2 ■“<* citrate on recombi­
nant RMFnc (wild type). Initial velocities were measured 
in the absence of effectors( • ) or in the presence of 1 JiM 
Fru-2,6-P2 (O) or 75 |1M citrate (#). The assay condi­
tions were the same as described in Section 2.2.4., Table 
6B and Figure 29. The equation for the MWC model (equa­
tion I) and the rectangular hyperbolic equation (equation 
II) were used to fit to the kinetic data.
The sum-of-squares values of these two types of 
curve fitting <I/II) are shown as follows: enzyme in the 
absence of effector (0.0019/0.11), enzvme In the presence 
of F-2.6-P^ (0.011/0.038), enzvme In the presence of
citrate (0.000 95/0.0045). The curves were drawn using the 
equation based on the MWC model.
The values of the parameters for both equations (I 
and II) are listed in Table 7.
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Figure 31. Effects of Fru-2,6-P2 end citrate on recombi­
nant RMPFK (Q200R). Initial velocities were measured in 
the absence of effectors(A ) or in the presence of 1 HM 
Fru-2,6-P2 (O) or 125 jam citrate (♦). The assay
conditions were the same as described in Section 2.2.4., 
Table 6B and Figure 29. The equation for the MWC model 
(equation I) (for describing the sigmoidal saturating 
curves) and the rectangular hyperbolic equation (equation 
II) were used to fit to the kinetic data.
The sum-of-squares values of these two types of 
curve fitting (I/II) are shown as the follows: enzvme in 
the absence of effector (0.040/0.17), enzvme in the pres­
ence of F-2.6-F^ (0.035/0.0043), enzvme in the presence
of citrate (0.00013/0.00099). The curves for the 
reactions in the absence of effector and in the presence 
of citrate were drawn using the equation based on the MWC 
model. The curve for the reactions in the presence of Fru 
2,6-P2 was drawn using the rectangular hyperbolic equa­
tion.
The values of the parameters for both equations are 
listed in Table 7.
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Figure 32. X£ftcfca of Fru-2,6-F2 end citrate on recoobi
nant RMPFK (Q200E). Initial velocities were measured in 
the absence of effectors(O) or in the presence of 10 nM 
Fru-2, 6-p2 (O) or 25 citrate (♦). The assay condi­
tions were the same as described in Section 2.2.4, Table 
6B and Figure 29. The equation for the MWC model (equa­
tion I) and the rectangular hyperbolic equation (equation 
II) were used to fit to the kinetic data.
The sum-of-squares values of these two types of 
curve fitting (I/II) are shown as the follows: enzyme In 
the presence of F-2.6-P^ (0.008/0.022), enzvme in the ab­
s e n c e  Qff .f if ff id L Q C  or enzvme in the presence of citrate 
could not be determined in this range. The curves were 
drawn using the equation based on the MWC model or using 
the linear regression program.
The values of the parameters used in both equations 
are listed in Table 7.
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Figure 33. Effects of Fru-2,6-?2 end citrate on recombi­
nant RMPFK (Q200A) . Initial velocities were measured in 
the absence of effectors(A) or in the presence of 10 JIM 
Fru-2,6-P2 (O) or 25 citrate (♦). The assay condi­
tions were the same as described in Section 2.2.4., Table 
6B and Figure 29. The equation for the MWC model (equa­
tion I) and the rectangular hyperbolic equation (II) were 
used to fit to the kinetic data.
The sum-of-squares values of these two types of 
curve fitting (I/II) are shown as follows: enzyme in the 
presence flf F-2.6-P^ (0.OlO/O.039), enzvme in the absence
Of effector or enzvme in the presence of citrate could not 
be determined in this range. The curves were drawn using 
the equation based on the MWC model or using the linear 
regression program.
The values of the parameters used in both equations 
are listed in Table 7.
Table 7
P>r— tirt for curve-fitting to the data of the wild typo RMPFK and tho throe octants
Enzyaa Effector MSC H ill
coefficient*R L Vaax sue-of 
■quarts
Vnax Kb aun-of
squares
NT
wr
WT
non* 
Fru 2,«-P2
C itra te
0.90 ±  0-019 
0.S7 ±  0.14 
4.5 ±  2.3
2900 X  3200
11 X  0.3 
1 8 ±  20
0.90 ±  0.02 0.0019
1.1 ±  0.03 0.011 
0.76 ±  0.17 0.00095
1.6 ±  0.46
1.2 ±  0.06
5 6 
1.6x10 ±  1.8x10
6.5 ±  0.37 0.11
1.2 ±  0.25 0.038
6 7 
3.5x10 ±  4.1x10 0.045
2.4 ±  0.43
1.4 ±  0.85
020(0 non* 0.079 X  0.034 1800 ±  1900 0.91 ±  0.021 0.040 1.0 ±  0.08 0.58 ±  0.16 0.17 1.9 ±  0.22
Q200R Fru 2.0 -P2 0.057 X  0.0090 54 X  32 0.99 ±  0.011 0.035 1.0 ±  0.03 0.12 ±  0.024 0.043 1.1 ±  0.17
Q200R C itra te 5.8 ±  0.84 1.7 X  0.60 0.84 X  0.051 0.00013 1.3 ±  0.21 15 ±  3.5 0.00099
Q200E non* 24 X  0-0 S.6 ±  5.3 0.52 ±  0.0S2 0.0044 0.72 ±  0.12 63 ±  20 0.0091 1.0 ±  0.40
Q200E Fru 2,6 -P2 0.34 X  0.042 7.2 ±  3.4 0.96 ±  0.17 0.008 1.0 ±  0.04 0.54 ±  0.07S 0.022 1.2 ±  0.27
Q200E C itn t* N.D. N.D. N.D. N.D. N.D. N.D. N.D.
0200ft nans N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D.
0200ft Fru 2,6 -P2 0.62 X  0.15 13 A 9.6 1.0 ±  0.34 0.01 1.1 ±  0.71 1.5 ±  0.30 0.039 1.1 ±  0.42
0200ft C itra te N.D. N.D. N.D. N.D. N.D. N.D. N.D.
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inhibition of the wild type and of all the mutants is 
reversed by Fru-2,6-P2. This suggests that mutations at 
position 200 have no effect on the binding site of the ef­
fector Fru 2,6-P2.
3.3.3. Justification of curve-fitting to kinetic 
data
The cooperativity of the binding of a substrate mol­
ecule to an allosteric enzyme is represented by a sigmoi­
dal saturation curve when enzyme activity is plotted vers­
es substrate concentration. The greater the cooperativi­
ty, the greater the sigmoidicity. Two equations were 
tested for curve-fitting to the saturation data: either 
the equation for the MWC model of allosteric behavior
(equation Is Y - C* [ <X/KR) * (1+ <X/KR) > 3] / [ (1+ (X/KR) ) 4+L])
or the equation for Michaelis-Menten rectangular hyperbol­
ic kinetics (equation II: Y * Vmax*X/Km+X) was used 
(Figures 29-33). The computer software package InPlot™ 
(Version 4.0) from Graph Pad (San Diego, CA) was used for 
curve-fitting and calculation of parameters based on these 
two equations. Each fit was evaluated by calculating a 
"goodness-of-fit" value, which is the sum-of-squares of 
the distances of the data points from the curve. Further­
more, each parameter for the equation used for curve-fit­
ting was assigned a standard error value. The magnitude
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of the standard error value relative to the value of the 
parameter itself indicates the confidence one can have 
that a given parameter is meaningful. In order to 
confidently analyze the cooperativity of the binding of 
the Fru 6-P molecule to the wild type enzyme and the three 
mutants, therefore, one must examine the validity of 
curve-fitting via goodness-of-fit values, the values for 
parameters themselves, and the standard error values as­
signed to the parameters. Table 7 shows 1) the goodness- 
of-fit (sum-of-squares) values, 2) the values for the
parameters <KR and L, or Vmax and Km) generated by
TMInplot and used in the equations, and 3) the values of 
the Hill coefficients for the wild type enzyme and the
three mutants. In the absence of Fru 2,6-p2» a comparison
of the goodness-of-fit to the cooperative curve based on 
the MWC model vs. the rectangular hyperbolic curve reveals 
a better fit to the cooperative curve (Figure 29). This 
is true not only for the wild type enzyme but also for the
two mutants Q200R and Q200E. A comparison of the KR val­
ues and the Hill coefficients of the wild type enzyme and 
the Q200R mutant indicates that the cooperative curve fits 
to the wild type enzyme data better than it does to the 
Q200R mutant data. Because the standard errors for the L- 
value of the wild type enzyme and the Q200R mutant are 
large, the parameters may not be suitable for predicting
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the origin of the enzyme's cooperative behavior. The co­
operative curve is not a good fit to the data for the 
Q200E mutant probably because saturation of this mutant by 
Fru 6-P is not achieved. These data demonstrate that the 
Q200R mutant is less cooperative than the wild type enzyme 
with respect to Fru 6-P binding in the absence of the ac­
tivator Fru 2,6-P2. The Q200E mutant has only a slight
cooperativity in the presence of 10-fold higher Fru 6-P 
concent r at i on.
The Fru 6-P saturation curves for the wild type en­
zyme and the three mutants {Figure 30-33) reveal that Fru
6-P binding is less cooperative after Fru 2, 6-P2 activa­
tion than before. This conclusion is supported by (1)
Hill coefficients close to unity upon activation by Fru
2,6-P2 and (2) small L-values upon activation by Fru 2,6-
P2 According to the MWC model (Monod et al., 1965), the
shape of the rapidly rising part of a sigmoidal saturation 
curve is dependent on the L-value. The larger the L-val- 
ue, the greater the sigmoidicity of the curve. When the 
L-value is small, there is only slight sigmoidicity, hence 
little cooperativity. Thus, the small L-values seen after
Fru 2,6-P2 activation indicate that the cooperativity of 
Fru 6-P binding is small in the presence of Fru 2,6-P2.
Ill
Goodness-of-fit values were used to evaluate 
curve-fitting to the two types of curves. It is notewor­
thy that, although cooperativity of Fru 6-P binding de­
creases, the saturation curves in the presence of Fru 2,6-
P2 fit better to the cooperative (MWC-based) curve than
to the rectangular hyperbolic curve. This is true for the 
wild type enzyme and the Q200E and Q200A mutants. The 
Q200R mutant data, however, fit to the rectangular hyper­
bolic equation slightly better than to the cooperative 
curve. Furthermore, the Vmax and Km values for the wild 
type enzyme and the three mutants indicate that the rect­
angular hyperbolic curve also fits validly to the data for
each enzyme in the presence of Fru 2,6-P2* Despite the
goodness-of-fit values and the values for Vmax and Km men­
tioned above, the Hill coefficients and the L-values as 
well as visual inspection indicate that the cooperativity 
of Fru 6-P binding to the wild type enzyme and the three
mutants decreases after activation by Fru 2,6-P2-
In the presence of citrate, the KR value and the L
value for the wild type enzyme and for the Q200R mutant 
show that the cooperative curve is probably not a good fit 
to the data for these two enzymes. This is because satu­
ration by Fru 6-P is not achieved in the presence of 
citrate. The Vmax value and the Km value for the wild
type enzyme also Indicate that the rectangular hyperbolic 
curve fits poorly to the data of the enzyme.
In summary, comparisons of the goodness-of-fit, the
Kr values calculated from the cooperative curve, and the
Hill coefficients indicate that the wild type enzyme data 
fit to the cooperative curve better than the Q200R mutant
data do in the absence of activator Fru 2,6-P2. A compar
ison of the L-values and the Hill coefficients before and
after activation by Fru 2,6-P2 demonstrates that Fru 6-F
binding to all the enzymes analyzed is less cooperative
upon Fru 2,6-P2 activation.
CHAPTER FOUR 
DISCUSSION
4.1 Sequence Diversity In the 5' Untranslated Region 
of RMPFK cDNA*
The results of the characterization of two full-length 
RMPFK cDNAs described in Section 3.1.3 show the sequence 
diversity in the 5" untranslated region of these cDNAs. 
Comparision with the upstream genomic sequence (courtesy of 
Dr. Z. Chen) indicates that cDNA-A (corresponding to cDNA 
65) is formed by a splicing event which removes a 1.7 Kb 
intron located upstream of the ATG codon while cDNA-B (cor­
responding to cDNA 13) retains at least the 3'-region of 
this intron. A comparison of the 5' untranslated regions 
of the two RMPFK cDNAs with those of the three HMPFK cDNAs 
(Figure 34) reveals that all five cDNAs share the same 
splicing acceptor sites located 8 bp 5' of ATG codon. 
However, sequences upstream of the splicing junction are 
different. Thus far, only one 5' exon has been found in 
each of these five cDNAs. These observations suggest 
strongly that transcription of both rabbit and human muscle 
PFK genes starts at multiple sites, and splicing subse­
quently takes place between a downstream splicing donor 
site and the common splicing acceptor site 8 bp upstream of 
the ATG codon.
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rigure 34. Comparison of the 5' untranslatad regions of two BHPFX cDNAs and thraa human muscle P1K cDNAs. (A) The
complete exon/intron organization of rabbit muscle PFK 
gene. Solid boxes, coding exon I through XXII; open boxes. 
upstream untranslated sequences; downward arrows, potential 
splicing donor sites; upward arrows, potential splicing ac­
ceptor sites; open triangles. SP1 sites; solid triangles. 
MyoD sites; open diamond, muscle specific enhancer. The 
1.7 Kb intron in cDNA-A (corresponding to cDNA 65) is indi­
cated by the downward bent line. The open box with a 
broken end indicates an untranslated region, the 5' end of 
which in not known. In cDNA-B (corresponding to cDNA 13) 
the 3' end of the upstream intron, hatched box, is contigu­
ous to Exon I of RMPFK gene. (B) Three human muscle PFK 
cDNAs (Nakajima et al., 1990). The dashed line and box in­
dicate an intron with unknown length and 5' untranslated 
sequence.
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4.1.1. Structural features In the promoter region 
of RMPFK gene
A 500 bp GC rich region (67 %) located in the up­
stream sequence of RMPFK gene contains 50 CpG sites (Bird/
1987) . As shown in Figure 34, various cis-elements exist 
in the promoter region of this gene: three SP1 binding 
sites (Roth et al., 1985), five MyoD binding sites (Aviv 
and Ledar, 1972), and one muscle specific enhancer (Deng 
and Wu, 1983). These elements may work coordinately with 
ubiquitous as well as muscle-specific transcription factors 
to assemble a transcription initiation complex. The 
TATAAAA sequence is found to exist in the untranslated re­
gion of cDNA-A. The transcription of this sequence casts 
doubt on the function of the TATA box in this gene. This 
problem has been resolved recently (see below).
More recently, colleagues in our laboratory have 
identified multiple transcription start sites for RMPFK 
gene by using primer extension method coupled with anchored 
polymerase chain reaction (Xiao, et al., manuscript in 
preparation). Sequences of the amplified DMA products have 
shown that transcription of this gene starts from a major 
site 27 bases downstream of the TATA box and from two sites 
which are TATA independent. This result indicates that the 
TATA box does indeed govern the major initiation event of 
the RMPFK gene transcription. The transcripts that begin 
at the two TATA-independent transcription sites are
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consistent with the sequences of RMPFK cDNA-A (#65) and B 
(#13), respectively, reported in this dissertation.
4.2 Expression and Purification of Recombinant 
RMPrK
Rabbit muscle PFK has been expressed at a signifi­
cant level in E. coli DF1020 cells by using the plasmid 
pPL2 as expression vector (Section 3.2). The recombinant 
enzyme was purified to homogeneity by affinity and anion 
exchange chromatography. The purified enzyme is essential­
ly identical to PFK isolated from rabbit skeletal muscle 
with respect to SDS-polyacrylamide gel electrophoresis 
mobility, Western blot patterns, and kinetic properties.
Several attempts have been made to use other E. coll 
expression systems, including the T7 promoter system and 
the tac promoter system, to express RMPFK. The major prob­
lem with using these systems is that the endogenous E. coll 
PFK activity contributes to that of the recombinant RMPFK 
to an undetermined extent, complicating the results during 
purification. Since the E. coli host DF1020 is deficient 
in EcPFK-1, we chose a pPL2/DF1020 system for the expres­
sion of recombinant RMPFK. With this system, PFK activity 
can be directly detected by growth of cells containing re­
combinant RMPFK on selective agar plates using mannitol as 
carbon source. This expression system has three advantages 
over other expression systems. First, DF1020 cells give a
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higher level of RMPFK expression than other E. coli 
strains. Second, growth on mannitol plates provides a vis­
ible selection for clones which express RMPFK. Third, E. 
coli PFK activity has been excluded in this system.
The availability of purified recombinant RMPFK 
provides the opportunity for a thorough kinetic study of 
the structure/function relationships of this enzyme. Dif­
ferent strategies have been employed to purify the cloned 
RMPFK. The addition of 0.5 mM ATP and protein inhibitor in 
the column buffer solves the problem of losing enzyme ac­
tivity during the purification steps. The combination of
<NH4)2S04 precipitation, affinity chromatography and anion
exchange chromatography provides us with a protocol to 
purify this cloned enzyme in four days and to have a high 
yield (49%) of pure enzyme.
Although the pPL2/DF1020 is not a super-expression 
system (the yield of the recombinant protein is no more 
than 30% of the total cellular protein) for RMPFK, it pro­
vides a sufficient level of expression. Approximately 1 mg 
of purified RMPFK can be obtained from 5 liters of cell 
culture. This scale is suitable for the enzymological 
studies reported here. We believe that the level of ex­
pression of RMPFK in bacterial host can be improved. There 
are 18 AGG/AGA arginine codons in RMPFK cDNA (Lee, et al., 
1987) These arginine codons are rarely used in E. coll 
cells (Wada et al., 1991). It would improve the expression
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of RMPFK in E. coli to use site-directed mutagenesis to 
change AGG/AGA codons into other arginine codons which are 
abundant in E. coli genes. Alternatively, introduction of 
a vector encoding an aginine tRNA (AGG/AGA) gene into a E. 
coll host would serve the same purpose (Brinkmann et al., 
1989) .
4.3 Site-Directed Mutagenesis
To probe the structure and function of RMPFK, we have 
applied the method of site-directed mutagenesis on the cDNA 
of this enzyme. Glutamine 200 was replaced with alanine, 
arginine, asparagine and glutamate. The mutated enzymes 
were purified to homogeneity by affinity and anion exchange 
chromatography.
One widely applied method of site-directed mutagene­
sis is that developed by Kunkel (1985). Theoretically, 
Kunkel's method is an efficient way to construct mutants.
In practice, however, this method involves the tedious pro­
cedure of screening for mutation, and has rather low yield 
(30%) of mutants. This low yield of mutants is assumed to 
be due to such factors as incomplete in vitro polymeriza­
tion, primer displacement by the DNA-polymerase 
used in the fill-in reaction, and the repair of the unmeth- 
ylated DNA strand (Kramer, et al., 1984).
The commercial "Altered Sites in vitro Mutagenesis 
System" has adventages over Kunkel's method in two
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important aspects: 1) The use of ampicillin selection for 
the mutation yields a high percentage (85 %) of mutants, 
and 2) the use of a special repair oligonucleotide 
eliminates the need for screening large numbers of colonies 
by hybridization. Two additional features of this system 
are the use of the repair-minus E. coli strain BMH71-18 mut 
S and the use of T4 DNA polymerase. The BMH71-18 mut S 
strain supresses in vivo mismatch repair (Zell and Fritz, 
1987). It is used in the first round of transformation, 
thus minimizing the chance of repairing the amber codon 
mismatch in the ampicillin resistant gene and the mutagenic 
mismatch in the cloned gene. T4 DNA polymerase is used in 
the synthesis reaction in place of Klenow fragment because 
the former does not displace the strand (Nossal, 1974) and 
therefore preserves the mutagenic oligonucleotide.
4.4 Mutation of Gln-200 to Arginina, Alanine or 
Glutamate
The chief aim of this study has been to investigate 
the structural role of Gln-200 in RMPFK during the R-T 
transition. The data presented in Section 3.3. demonstrate 
that mutations of Gln-200 (which is located in the hypo­
thetic 6-F loop of RMPFK) affect the enzyme's kinetics dra­
matically. The residue at position 200 of RMPFK has been 
substituted with amino acids having charged side chains or 
a smaller uncharged side chain. Mutation of Gln-200 to
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arginine causes an elevation in affinity for Fru 6-P along 
with a reduced cooperativity of Fru 6-P binding. Mutation 
to alanine or glutamate results in a drastic reduction of 
activity of the enzyme under the same conditions. The 
condition used for analyzing the allosteric properties of 
RMPFK PFK in these studies was 7 mM ATP, which is required 
for the maximum activity of the Q200R mutant at pH 7.0.
The MWC model (Monod et al., 1965) is used in this discus­
sion as the conceptual framework for understanding 
allosteric properties of the wild type and the mutants 
RMPFK, although the truth is undoubtedly more complex than 
this simple two-state model (see Section 3.3.3).
The kinetic properties of the Q200R mutant suggest 
that changing the Gin at position 200 to a positively 
charged residue causes the enzyme to have an R state-like
conformation. The SQ 5 p̂ru g_p) of this mutant is 4-fold
less than that of wild type RMPFK. The cooperativity of 
this mutant for Fru 6-P binding decreases (n ■ 1.9, com­
pared to 2.4 for wild type RMPFK). The substitution of 
Gln-200 with Arg seems to stabilize the R-state conforma­
tion.
The kinetics of the Q200A mutant with respect to 
[Fru 6-PI suggest that it has a quaternary structure simi­
lar to the inactive, T state structure. This mutant can 
not achieve half-saturation at pH 7.0 in the absence of Fru
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2,6-P2* even with a concentration of Fru 6-P over 200 mM. 
However, it does achieve half-saturation at low concentra­
tion of Fru 6-P in the presence of activator, Fru 2,6-P2 at
pH 7.0, or at pH 8.0,
The mutation of Gln-200 to a negatively charged resi­
due, glutamate, may lead to a perturbation of the Fru 6-P
binding site of RMPFK. The Sg,5(pru g_pj of mutant Q200E
is much greater than that of wild type. Moreover, the 
Q200E mutant has higher sensitivity to citrate inhibition.
In spite of their extremely low activities at high 
concentration of Fru 6-P, mutants Q200A and Q200E can be
activated by Fru 2,6-P2 to reach the wild type activity
level. These results suggest that glutamine at position
200 is not involved in the binding of Fru 2,6-P2.
In BsPFK, the structural changes at the substrate 
binding site during the T to R transition result in an 
interaction between Arg-162 and phosphate of Fru 6-P. 
Concomitantly, Glu-161 switchs out of the substrate binding 
cleft (Schirmer and Evans, 1990). The x-ray crystal 
structure of BsPFK in the R state shows that Glu-161 forms 
an indirect interaction with residue His-39 (P. R. Evans, 
personal communication). A proposed H39:E161 ion pair may 
stabilize the R-state conformation of BsPFK. A description 
of the possible interactions between residue 39 and 161 or
their equivalents in different species is presented in 
Table 8. Glu-53 in RMPFK is equivalent to His 39 in BsPFK. 
BsPFK is the only one to have both a basic residue at posi­
tion 39 and an acidic one at position 161. This H39:E161 
interaction is consistent with a hyperbolic kinetic profile 
of BsPFK with respect to Fru 6-P (Valdez et al., 1989).
The putative interaction between His-39 and Glu-161 may 
play a major role in stabilizing the R state conformation.
In RMPFK, the residue at position 200 (corresponding 
to Glu-161 in BsPFK) is glutamine, and residue at position 
53 (corresponding to His-39 in BsPFK) is glutamate. The 
Q200R mutation may give the enzyme a more R state like con­
formation, while the Q200A and the Q200E mutations may give 
the enzyme a more T state like conformation. These results 
are consistant with predicted interaction between Gln-200 
and Glu-53 in RMPFK. Mutation at Glu-53 has to be conduct­
ed to determine whether or not an interaction between Gln- 
200 and Glu-53 is important for stabilizing the R state 
conformation.
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Table 8.
The possible interaction between residues #39 4 #161 indifferent PVK species
PFK Species
Residue
39
#
161
Mammal N-half E Q
Yeast N-half E S
Mammal C-half D K
Yeast C-half (A/B) N R/G
E. coli D Q
B. stearothermophilus H E
The residues presented for yeast and mammalian PFK's are 
those in positions corresponding to residues #39 and #161 
of the bacterial enzymes. (P. R. Evans's personal communi­
cation)
CHAPTER FIVE 
SUMMARY
Two full-length cDNAs of RMPFK have been purified 
and characterized. The sequence evidence shows that the 
two cDNAs are identical in their coding region but are 
different in their 5'-untranslated region, a result sug­
gesting multiple promoters and transcription start sites 
in the gene of RMPFK.
The coding region of RMPFK cDNA has been cloned in 
several expression vectors, including pET-3c which uses a 
T7 phage promoter, and pPL2 which is controlled by the PL 
promoter of lambda phage. The latter vector was chosen 
for the expression of RMPFK in E. coli host DF1020. This 
system provides a visible selection for clones which pro­
duce RMPFK and it is free of endogenous PFK activity. Re­
combinant RMPFK has been purified and shown to resemble 
the PFK purified from rabbit muscle with respect to physi­
cal and enzymatic properties.
On the basis of amino acid sequence similarity be­
tween RMPFK and BsPFK and the crystal structure of the 
latter, the glutamine residue at position 200 of RMPFK has 
been substituted by arginine (Q200R), alanine (Q200A) and 
glutamate (Q200E). Under the conditions of pH 7.0 and 7
mM ATP, the Q200R mutant has a 4-fold lower Sq 5(pru 6-P)
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than the wild type RMPFK, the Q200A mutant is essentially
inactive, and the Q200E mutant has an activity lower than 
that of the wild type RMPFK, even at much higher concen­
trations of Fru 6-P. The cooperativity of Fru 6-P 
binding, as measured empirically by the Hill coefficient, 
is lower for the Q200R mutant and for the Q200E mutant 
than for the wild type RMPFK, The recombinant RMPFK and
the three mutants are all activated by Fru 2,6-P2.
ABBREVIATIONS
BSA - Bovine serum albumin
BsPFK - Bacillus stearothermophilus PFK
C-type PFK - Brain isozyme of PFK
cAMP - 3', 5'-cyclic AMP
cDNA - Complementary DNA (transcribed or copied
from mRNA) 
ddA - Dideoxy ATP
ddC - Dideoxy CTP
DMSO - Dimethylsulfoxide
DTT - Dithiothreitol
EcPFK-1 - Major EcPFK
EcPFK - Escherichia coli PFK
EDTA - Ethylenediaminetetraacetic acid
Fru 1,6-P2 - Fructose 1,6-bisphosphate
Fru 2,6-P2 - Fructose 2,6-bisphosphate
Fru 6-P - Fructose 6-phosphate
HLPFK - Human liver PFK
HMPFK - Human muscle PFK
hr - hour
Km - Michaelis constant
Kb - Kilobase pairs
LB - Luria-Bertani
L-type PFK - Liver isozyme of PFK
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MLPFK - Mouse liver PFK
M-type PFK - Muscle isozyme of PFK
NAD - Nicotinamide adenine dinucleotide
NADH2 - Nicotinamide adenine dinucleotide
(reduced) 
nt - Nucleotide
PAGE - Polyacrylamide gel electrophoresis
PEG - Polyethylene glycol
PFK - 6-Fhosphofructo-l-kinase
Pi - Inorganic phosphate
PMSF - Phenylmethylsulfonyl fluoride
Q200A - Gln-200 to Ala mutant
Q200E - Gln-200 to Glu mutant
Q200N - Gln-200 to Asn mutant
Q200R - Gln-200 to Arg
RF - Replicative form
RMPFK - Rabbit muscle PFK
Sq ^ - Half-saturation concentration
SDS - Sodium dodecylsulfate
SDS-PAGE - SDS polyacrylamide gel electrophoresis
TAE - Tris-Acetate EDTA buffer
TBE - Tris-Borate EDTA buffer
TCA - Tricarboxylic acid cycle
TEMED - N, N. N', N'-tetramethylethylenediamine
Tris.HCl - Tris(hydroxymethyl) aminomethane chloride
YT - Yeast/Tryptone
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Appendix Z
Aliganut of DMA ■•quwiota of rabbit muscle PFK cDNA- 13 (top) and cDNA-65 (bottom) in tha coding rag ion and tha 3' untranslatad ragion.
Alignment was started from the ATG codon to the 3' 
untranslated region.
1 ATGAC C CATGAAGAGCAC CATGCAGCCAGAAC C C TGGGGGTCGGCAAGGC 50
1 ATGAC C CATGAAGAGCAC CATGCAGC CAGAAC C CTGGGGGTCGGCAAGGC 50
51 CATCGCGGTGCTCACCTCCGGCGGAGATGCCCAAGGTATGAATGCTGCCG 100
51 CATCGCGGTGCTCACCTCCGGCGGAGATGCCCAAGGTATGAATGCTGCCG 100 
* • * * *
101 TCCGGGCTGTGGTTCGAGTTGGCATCTTCACTGGTGCCCGGGTCTTCTTC 150l l l t l l l l l l l l l l l f l l l l l l l l l l l l l l l l l l l l l l l l l l l j l l l l l l
101 TCCGGGCTGTGGTTGCAGTTGGCATCTTCACTGGTGCCCGGGTCTTCTTC 150 
■ • • » •
151 GTCCATGAGGGCTACCAGGGCCTGGTGGATGGCGGGGACCACATCCGGGA 200
I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
151 GTCCATGAGGGCTACCAGGGCCTGGTGGATGGCGGGGACCACATCCGGGA 200 
201 GGCCACGTGGGAGAGCGTCTCCATGATGCTGCAGCTGGGAGGCACCGTGA 250
llllllllllllllllllllllllllllllllllllllllllllllllll
201  GGCCACGTGGGAGAGCGTCTCCATGATGCTGCAGCTGGGAGGCACCGTGA 250 
251 TTGGAAGTGCTCGGTGCAAGGACTTCCGGGAGCGAGAGGGACGTCTCCGA 300 
251 TTGGAAGTGCTCGGTGCAAGGACTTCCGGGAGCGAGAGGGACGTCTCCGA 300 
301 GCCGCCCACAACCTGGTGAAGCGTGGGATCACCAATCTGTGTGTGATAGG 350
llllllllllllllllllllllllllllllllllllllllllllllllll
301 GCCGCCCACAACCTGGTGAAGCGTGGGATCACCAATCTGTGTGTGATAGG 350 
351 CGGTGATGGCAGCCTCACTGGGGCTGATACCTTCCGTTCTGAGTGGAGCG 400
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
351 CGGTGATGGCAGCCTCACTGGGGCTGATACCTTCCGTTCTGAGTGGAGCG 400 
• * * « •
401 ACCTGTTGAGTGACCTCCAGAAAGCGGGTAAGATCACAGCCGAGGAGGCC 450                  j 1 1 1 1 1  n  i j f i f 1 1 1 1 1 1 1 1 1 1 1  m  1 1
401  ACCTGTTGAGTGACCTCCAGAAAGCGGGTAAGATCACAGCCGAGGAGGCC 450 
451 ACGAGGTCCAGCTACCTGAACATCGTGGGCCTGGTCGGCTCCATTGACAA 500
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
451  ACGAGGTCCAGCTACCTGAACATCGTGGGCCTGGTCGGCTCCATTGACAA 500 
501  TGACTTCTGCGGTACGGATATGACCATCGGCACCGACTCTGCCCTGCACC 550I I I I I I I I I I I I I I I I I I I I I I I I I I I I I U I I I I I I I I I I I I I I I I I I I
501  TGACTTCTGCGGTACGGATATGACCATCGGCACCGACTCTGCCCTGCACC 550 
551 OGATCACAGAGATTGTGGATGCCATCACCACCACTGCCCAGAGCCACCAG 600 
551  GGATCACAGAGATTGTGGATGCCATCACCACCACTGCCCAGAGCCACCAG 600 
601  AGGACATTTGTGTTAGAAGTGATGGGCCGCCACTGTGGATACCTGGCCCT 650l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l i l l l l l l l l l l l l l l l l l
601  AGGACATTTGTGTTAGAAGTGATGGGCCGCCACTGTGGATACCTGGCCCT 650
134
^8914^^^4990429655
548636832822981^^^
^^8011809543295095
196452958^73821^^^
651 GGTCACCTCTCTGTCCTGC GGTGCTGACTGGGTCTTCATTCC TGAGTGTC 700I 1 I I I I I I I I I I I t I I I I I I I I I I I I I I I I I I I I I I t I I I I I I I I I I I I I
651 GGTCAC CTC TCTGTC C TGC GGTGCTGAC TGGGTCTTCATTC C TGAGTGTC 700
• • * i «
701 CTCCGGATGACAACTGGGAGGATCACCTGTGTCGCCGGCTCAGTGAGACA 750I I I I I I I I I I I I I I I I I I I I I I I I 1 I I I I I I I I t I I I I I f I I I I I I I I I I
701 CTCCGGATGACAACTGGGAGGATCACCTGTGTCGC CGGCTCAGTGAGACA 750 
751 CGGACCCGTGGCTCTCGCCTCAACATCATCATTGTGGCCGAGGGTGCAAT 800I I I I I I I I I I I I I I I I I I I I I I ! I I I I I I  I I I I I I I I I I I I 1 I I I I I I I I
751 CGGACCCGTGGCTCTCGCCTCAACATCATCATTGTGGCCGAGGGTGCAAT 800 
801 CGACAGGAACGGGAAACCGATCACCTCAGAAGGCGTCAAGGATCTGGTGG 850I I I I I I I I I I I I I I N  .....
801 CGACAGGAAC GGGAAAC C GATCAC CTCAGAAGGC GTCAAGGATCTGGTGG 850
* • * • »
851 TGAAGCGTCTGGGCTATGACACGCGGGTCACCGTCCTGGGGCATGTGCAG 900I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 1 1  I I I t I I I I I I I
851 TGAAGCGTCTGGGCTATGACACGCGGGTCACCGTCCTGGGGCATGTGCAG 900 
901 CGAGGTGGAACCCCCTCAGCCTTCGACAGGATCCTGGGCAGCAGGATGGG 950l i l l l i m i l M l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
901 CGAGGTGGAACCCCCTCAGCCTTCGACAGGATCCTGGGCAGCAGGATGGG 950 
* * * ♦ •
951 CGTGGAAGCAGTGATGGC GCTGTTGGAGGGGAC C C C GGACAC CC CGGCCT 1000I I I I I I I I I I I I I I I I I I I I I f j  I I I I I I I I I I I I I I f I I I ! I I I I I I I I
951 CGTGGAAGCAGTGATGGC GC TGTTGGAGGGGAC C C C GGACACCC CGGC CT 1000 
1001 GTGTGGTGAGCCTGTCTGGTAACCAGGCCGTGCGCCTGCCGCTCATGGAA 1050
I I I I I I I I I I I I I 1 I I I I I I I t I ! I I ! I I I I I I I t I I I I I I I I I I I I I I I
1001 GTGTGGTGAGCCTGTCTGGTAACCAGGCCGTGCGCCTGCCGCTCATGGAA 1050 
1051 TGTGTCCAGGTGACCAAAGATGTGACCAAGGCCATGGACGAGAAGAGATT 1100I I I I I I i I I I I I I I I I I I I I I 1 I 1 I I I i I I I i  I I I f l  I I I I I I I I I I I I  I
1051 TGTGTCCAGGTGACCAAAGATGTGACCAAGGCCATGGACGAGAAGAGATT 1100 
1101 TGATGAAGCCATGAAGCTGAGAGGCCGGAGCTTCATGAACAACTGGGAGG 1150I I I I I I I I I I I I I  I I I I I I I I f  I I I I I I I I t I I I I I I I I I I I I ( I I I I I I
1101 TGATGAAGCCATGAAGCTGAGAGGCCGGAGCTTCATGAACAACTGGGAGG 1150 
1151 TGTACAAGCTTCTGGCTCACATCAGACCCCCAGCCCCCAAGAGTGGCTCG 1200I I I  I I  I I I I  I I I I I I  I I I  I I I I I I  I I  I I  I I I  I M i l  I I I  M i l  I I I I  I I I
1151 TGTACAAGCTTCTSGCTCACATCAGAC CCCCAGC C C CCAAGAGTGGCTC G 1200 
1201 TACAC CGTAGCTGTGATGAAC GTGGGTGCC C CGGCGGCAGGCATGAATGC 1250l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
1201 TACACCGTAGCTGTGATGAACGTGGGTGCCCCGGCGGCAGGCATGAATGC 1250
* • i * I
1251 AGCTGTTCGCTCCACTGTGAGGATTGGCCTGATCCAGGGCAACCGGGTGC 1300l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
1251 AGCTGTTCGCTCCACTGTGAGGATTGGCCTGATCCAGGGCAACCGGGTGC 1300 
1301  TGGTGGTGCAC GATGGCTTCGAGGGGC CTGC CAAGGGC CAGATTGAGGAA 1350l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l t l l l l l l l l l l l  , . A1301 TGGTGGTGCACGATGGCTTCGAGGGGCCTGC CAAGGGCCAGATTGAGGAA 1350 
1351 GCCGGCTGGAGCTACGTAGGGGGCTGGACCGGGCAAGGCGGCTCCAAACT 1400l l l l l l l l l l l l l l l l l l l l l l l l l l l l l f l l l l l l l l l l l l l l l l l l l l
1351  GCCGGCTGGAGCTACGTAGGGGGCTGGACCGGGCAAGGCGGCTCCAAACT 1400
262909681308
1401  GGGCACTAAAAGGACTC TACC CAAAAAGAGC TTCGAAC AGATCAGTGC CA 1450
I I I I I I I I I I I I I I I I f I I I t I I I I I I I I I | I I | | | | | | I | | | | | | | I | |
1401 GGGCACTAAAAGGACTCTACCCAAAAAGAGCTTCGAACAGATCAGTGCCA 14 50 
1451 ACATAAC C AAGTTTAAC ATCCAGGGC CTGGTCATC ATTGGGGGC TTTGAG 1500l l l l l l l l l l l l l l l l l l l l l l l l l i n n i l l l l l l l l t l l l t l f l l l l
1451 ACATAAC C AAGTTTAAC ATC CAGGGCCTGGTC ATC ATTGGGGGC TTTGAG 1500
• *, ■ ■ a
1501 GCTTACACCGGGGGCCTGGAGCTGATGGAGGGCAGGAAGCAGTTTGACGA 15501 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1  i 1 1 1 1 1 1 1 1 1 1 1 1 1  f 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
1501 GCTT ACAC C GGGGGC CTGGAGC TGATGGAGGGCAGGAAGCAGTTTGAC G A 1550 
1551 GCTCTGCATCCCTTTCGTGGTCATCCCTGCCACAGTCTCCAACAACGTTC 1600l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
1551 GCTCTGCATCCCTTTCGTGGTCATCCCTGCCACAGTCTCCAACAACGTTC 1600 
1601 CCGGCTCAGACTTCAGCGTCGGGGCGGACACGGCGCTCAACACCATCTGC 1650I I I i I I I I I I I I I 1 I I I t I I I I I I I I I | I I I I I I I I I I I | 1 I I I I I I I I I
1601 CC GGCTCAGACTTC AGCGTC GGGGC GGACAC GGC G CTCAACAC CATCTGC 1650 
1651 AC GACGTGTGAC CGTATCAAGCAGTC C GC AGCGGGC AC CAAGC GC C GGGT 1700I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I j I I I I I I I I I II I I
1651 ACGACGTGTGACCGTATCAAGCAGTCCGCAGCGGGCACCAAGCGCCGGGT 1700 
1701 GTTCATCATCGAGACCATGGGCGGCTACTGCGGCTACCTGGCCACCATGG 1750 
1701 GTTCATCATCGAGACCATGGGCGGCTACTGCGGCTACCTGGCCACCATGG 1750 
1751 CAGGACTGGCAGCCGGGGCCGATGCTGCCTACATTTTTGAGGAGCCCTTC 1800l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
1751 CAGGACTGGCAGCCGGGGCCGATGCTGCCTACATTTTTGAGGAGCCCTTC 1800 
1801 ACCATCCGAGACCTGCAGGCGAATGTTGAACACCTGGTGCAAAAGATGAA 1850l l l l l l l l l l l l l l l l l l l l l l l l l f  l l l l l l l l l l i l l l l l l  l l l l l l l
1801 ACCATCCGAGACCTGCAGGCGAATGTTGAACACCTGGTGCAAAAGATGAA 1850 
1851 GACGACTGTGAAGAGAGGCTTGGTGCTGAGGAACGAGAAGTGCAATGAGA 1900
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
1851 GACGACTGTGAAGAGAGGCTTGGTGCTGAGGAACGAGAAGTGCAATGAGA 1900 
1901 ATTACACCACGGACTTCATCTTCAACCTGTACTCTGAGGAGGGGAACGGC 1950I I  I I  I I I  I I l l l l  I I  I I  I I  I I I I  I I I  I I I  I I I  I I  I I I  I I I  l l l l I I I I  I I
1901 ATTACACCACGGACTTCATCTTCAACCTGTACTCTGAGGAGGGGAAGGGC 1950 
1951 ATCTTCGACAGCAGGAAGAACGTGCTTGGCCACATGCAGCAGGGCGGGAG 2000l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
1951 ATCTTCGACAGCAGGAAGAACGTGCTTGGCCACATGCAGCAGGGCGGGAG 2000  
2001  CCCCACTCCCTTTGACAGGAACTTTGCTACTAAGATGGGAGCCAAGGCCA 2050i m i m m i i m m i i i i i i i i i m m i i i i i i i i i i i i i i i i
2001  CCCCACTCCCTTTGACAGGAACTTTGCTACTAAGATGGGAGCCAAGGCCA 2050 
2 0 5 1  TGAACTGGATGGCTGGGAAGATCAAGGAGAGTTACCGCAACGGGCGGATC 2100I f l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
2051  TGAACTGGATGGCTGGGAAGATCAAGGAGAGTTACCGCAACGGGCGGATC 2100 
2101  TTCGCCAACACCCCTGACTCCGGCTGTGTTCTGGGAATGCGTAAGAGGGC 2150t l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
2101  TTCGCCAACACCCCTGACTCCGGCTGTGTTCTGGGAATGCGTAAGAGGGC 2150
^^6652525449955794
21S1 TCTGGTCTTCCAACCAGTGACTGAGCTGCAGAATCAGACGGACTTTGAGC 2200
1111 f 11111111111111111111111111111111! 11111111111 i
2151  TCTGGTCTTCCAACCAGTGACTGAGCTGCAGAATCAGACGGACTTTGAGC 2200  
2201  ACCGAATCCC C AAGGAACAGTGGTGGC TGAAGCTGCGGCCCATCCTCAAA 2250t I I I I I I I I I I 1 I i I I I t I I t I I I I ! I I I I I I I I I I I I I I I i I I I | I i I |
2201 ACCGAATC CC CAAGGAAC AGTGGTGGCTGAAGCTGC GGCC CATC CTCAAA 2250 
2251  ATCCTAGCCAAGTACGAGATTGACTTGGACACCTCCGAGC ACGCGCATCT 2300I I I I  I I I I I I I I I I I I I t I I I I  I I I I I I I I I I I I t I t I I I I I I I I I I  I I I
2251  ATCCTAGCCAAGTACGAGATTGACTTGGACACCTCCGAGCACGCGCATCT 2300 
2301  GGAGCACATCTC CCGGAAGC GGTCTGGGGAAGC C ACCGTCTAAGCCTCGG 2350I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I
2301  GGAGCACATCTCCCGGAAGCGGTCTGGGGAAGCCACCGTCTAAGCCTCGG 2350 
2 351 AGCGAGGGACAGGCTGTCTGATCACATCAAAGATGCACGCCGTGTCCATG 2400
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I ! I I I I I I I I I I I I I
2 351 AGCGAGGGACAGGCTGTCTGATCACATCAAAGATGCACGCCGTGTCCATG 2400  
2401  TCGTAGCTCTTTAGTCATTAGGGTCCCTGTACTTGTGCACCCAAGGCCGT 24 50
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
2401 TCGTAGCTCTTTAGTCATTAGGGTCCCTGTACTTGTGCACCCAAGGCCGT 2450  
2451 GACCAGCTCTGGCCGGGAACCGGGAGCATGCAGTAGGTGGAAGCTCCTGT 2500
I I I I I I I I I I I I I I I I I I I I I I I ( II I I I I I I I I I I I II I I I I I I II IM
24 51 GACCAGCTCTGGCCGGGAACCGGGAGCATGCAGTAGGTGGAAGCTCCTGT 2500  
2501  AGTAGACTCGGTCATGACCCGCACCCCAGCCTGGTCTGTTACACAGGCAG 2550I I I I I I I I I I I I I I I I I I I I I I  I I I I I I I  I I I I I I I I I I I I I I I I I I I I I
2501  AGTAGACTCGGTC ATGACC C GC AC CCCAGC C TGGTCTGTTAC ACAGGCAG 2550  
* • * # •
2551  GGTCCTGTAGTGCTCCTGCTGGACCACACAGGTAGAACTCCCTTTACACG 2600I I I I I I I I I I I I I I I I I I I I I I I I I t I I I I I I I I I I I I I I I I I I I I I I I I
2551  GGTCCTGTAGTCCTCCTGCTGGACCACACAGGTAGAACTCCCTTTACACG 2600
« • • » t
2601  CGCTTTATTTATTTCTTTGTGTTAACAAGAGTGTCGGCTTCTCACACTCC 2650I I I
2601  CGC........................................................................................................................  2603
Appendix II 
Sequences ot Synthetic Oligonucleotides
A. Linkers for subcloning
Code Sequence (S' to 3')
pET-Xba
CTAGCAATAATTTTGTTTAACTTTAAGAAGGAGTCTAGACCCGGGGGTAC 
pET-Kpn CCCCGGGTCTAGACTCCTTCTTAAAGTTAAACAAAATTATTG 
PL2-Cla CGATTAAGGAGGTCTAGACTGATATCGGTACCCAGC 
PL2-Sac GGGTACCGATATCAGTCTAGACCTCCTTAAT
B. Primers for in vitro mutagenesis and DNA sequencing
Code Sequence (S' to 3') Start Position Remarks
(nt)
PFK1X ATGACCCATGAAGAGCACCATGC 1 sequencing primer
PFK1XC GGCTGCATGGTGCTCTTCATGGGTC 27 sequencing primer
PFK2 TCCGAGCCGCCCACAAC 298 sequencing primer
PFK3 AATGACTTCTGCGGTAC 499 sequencing primer
PFK4 TGTCCTCCGGATGACAAC 697 sequencing primer
PFK6 GCCATCCAGTTCAT 1061 sequencing primer
PFK7 CTGGAGCACATCTCCCG 2298 sequencing primer
Ala200 GCCCAGAGCCACGCGAGG
ACATTTGTG
586 make Gln-200 to 
Ala mutant
138
Arg200 AGAGCCACCGGAGGACATTTG 591 make Gln-200 to
Arg mutant
Glu200 AGAGCCACGAGAGGACATTTG 591 make Gln-200 to
Glu mutant
Appendix III
Amino Acid smqumnce of the recombinant PMPI7C
This amino acid sequence was generated from the 
Sequence Analysis Software Package of the Genetic 
Computer Group (GCG) (University of Wisconsin 
Biotechnology Center).
1 HTHEEHHAAR TLGVGKAIAV LTSGGOAQGH naavravvrv G lFTG A R vrr
51 VHEGYQGX.VD GGDHZREATW ESVSMHLQLG GTVIGSARCK DFREREGRLR
101 AAHNLVKRGI TNLCVIGGDG SLTGAOTFRS EWSDLLSDLQ KAGKZTAEEA
151 TRSSYLNIVG tVGSIDNDFC GTDHTIGTDS ALHRZTEZVD AITTTAQSHQ
201 RTFVLEVWGR HCGYLALVTS LSCGADWVFZ PECPPDDNWE OHLCRRLSET
251 RTRGSRLNII IVAEGAIDRN GICPITSEGVK DLWKRLGYD TRVTVLGHVQ
301 RGGTPSAFDR ILGSRHGVEA VHA1XBGTPD TPACWSLSG NQAVRLPLME
351 CVQVTKDVTK AHOEKRFOEA HKLRGRSFMN NWEVYKLLAH IRPPAPKSGS
401 YTVAVMNVGA PAAGMNAAVR STVRIGLIQG NRVLWKDGF EGPAKGQIEE
451 AGWSYVGGWT GQGGSKLGTK RTLPKKSFEQ ISAWITKFNI QGLVIIGGFE
501 AYTGGLELME GRKQFDELCI p rw iP A T V S NHVPGSOFSV GADTALNTIC
551 TTCDRIKQSA AGTKRRVFII ETMGGYCGYL ATHAGLAAGA DAAYIFEEPF
601 TIRDLQAHVE KLVQKMKTTV KRGLVLRNE1C CNEWYTTDF1 FNLYSEEGXG
651 IFDSRKNVLG HHQQGGSPTP FDRNFATKMG AKAHNWHAGK IKESYRNGR1
701 FANTPDSGCV LGHRKRALVF QPVTELQNQT DFEHR1PKEQ WWLKLRPILX
751 ILAKYEIDLD TSEHAHLEHI SRXRSGEATV *
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Appendix IV
Restriction Cutting Sites end DMA Sequence of the Coding Region of The rull Length RMFFK cDNA
This cDNA map was generated from the Sequence 
Analysis Software Package of the Genetic Computer Group 
(GCG) (University of Wisconsin Biotechnology Center).
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Appendix V 
Coroon Solutions/Reagents
LB (Luria-Bertani) Medium: 
Per litter:
Bacto-tryptone 
Bacto-yeast extract 
NaCl
Adjust pH to 7.5
2 x YT Medium:
Per litter:
Bacto-tryptone 
Bacto-yeast extract 
NaCl
Adjust pH to 7.5
NZY Medium:
Per litter:
NaCl
MgSO^.7H20
Yeast extract 
NZ Amine
M9 Medium:
10 x M9 Salt: 500 ml
Na2HP04
kh2po4
nh4ci
NaCl
Mix CaCl2, MgS04, glucose, 
H20 just before use.
TYP Medium:
Per litter:
Bacto-tryptone 
Bacto-yeast extract 
NaCl
k2hpo4
SM Buffer:
Per litter:
NaCl
MgS04
Tris-Cl (pH 7.5)
10 g 
5 g 
10 g
16 g 
10 g 
10 g
5 g 
2 g
5 g 10 g
30 g 
15 g 
5 g
2.5 g
thiamine and 1 x M9 salt with
16 g 
16 g 
5 g2.5 g
5.8 g
2 g50 ml of 1 M stock
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20 x SSC:
Per litter:
NaCl
sodium citrate 
Adjust pH to 7.0
20 x SSPE
3.6 M NaCl
200 mM NaH2P04 (pH 7.4)
20 mM EDTA (pH 7.4)
50 x Denhardt's Solution:
500 ml:
Ficoll 5 g
Polyvinylpyrrolidone 5 g
BSA 5 g
Filter through a Nalgene filter.
Dispense into 50 ml aliquots and store at -20°C.
Prewashing Solution:
50 mM Tris-Cl (pH 8.0)
1 M NaCl 
1 mM EDTA 
0.1 % SDS
Prehybridization Solution:
50 % foramide 
5 x Denhardt's solution 
5 x SSPE
0.1 % SDS
100 fig/ml denatured, salmon sperm DNA
TE (Tris-EDTA):
10 mM Tris-Cl (pH 8.0)
1 mM EDTA
50 x TAE (Tris-Acetate-EDTA):
Per litter:
Tris base
glacial acetic acid
0.5 M EDTA
5 x TBE (Tris-Borate):
Per litter:
Tris base 
Boric acid
0.5 M EDTA
242 g 
57.1 ml 
100 ml
54 g 
27.5 g 
20 ml
175.3 g 
88.2 g
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Lysozyme Solution (Solution I):
50 mM glucose 
10 mM EDTA
25 mM Tris-Cl (pH 8.0)
4 mg/ml lysozyme 
Add powdered lysozyme to the solution just before use,
Solution II:
0.2 N NaOH 
1 % SDS
3 M Potassium Acetate, pH 4.8 (Solution III):
To 60 ml of 5 M potassium acetate add 11.5 ml of glacial 
acetic acid and 28.5 ml H20. The resulting solution is
3 M with respect to acetate.
Phage Precipitation solution:
3.75 M ammonium acetate, pH 7.5 
20 % polyethylene glycol (MW 8,000)
% Sequencing gel:
Per 500 ml:
40 % acrylamide 
2 % bis-acrylamide 
urea 
5 x TBE
71.2 ml 
75 ml 
230 g 
50 ml
Filter through 3MM Whatman filter paper and store in a 
brown bottle.
Competent Cells Solutions:
RF1:
Per litter:
RbCl
MnCl2.4H20
potassium acetate 
CaCl2.2H20
(pH 7.5)
12 g 
9.9 g
30 ml of a 
1.5 g
150 g
1 M stock
Glycerol
Adjust the pH to 5.8 with 0.2 M acetic acid. Sterilize 
by filtration through a pre-rinsed 0.22 pm membrane.
RF2:
Per litter:
MOPS (pH 6.8) 
RbCl
CaC12.2H20 
Glycerol
20 ml of a 
1.2 g 
11 g 
150 g
0.5 M stock
Adjust pH to final pH 6.8 with NaOH and sterilize by 
filtration through a pre-rinsed 0.22 pm membrane.
Laemmll Solutions (for SDS separating ael):
30 % aerylamide/0.8 % bisacrylamide 
Per 200 ml:
Aerylamide 60 g
N',N-methylene-bisacrylamide 1.6 g
Filter through a 3 MM Waterman paper and store at
a brown bottle.
4 x Stacking Gel Buffer, pH 6.8 {0.5 M Tris-Cl)
Per 100 ml:
Tris Base 6.05 g
Adjust pH to 6.8 with 1 N HC1.
4 x Running Gel buffer, pH 8.8 (1.5 M Tris-Cl)
Per 500 ml:
Tris Base 91 g
Adjust pH to 8.8 with 1 N HC1.
2 x SDS/sample buffer:
Tris base 0.76 g
glycerol 10 ml
SDS 1 g
2-mecaptoethanol 1 ml
Bromophenol Blue 0.5 mg
Adjust to pH 6.8.
SDS Running Tank buffer, pH 8.3:
Tris base 12 g
glycine 57.6 g
SDS 4 g
Adjust volume to 4 litters.
Western Blotting Solutions:
Transfer Buffer:
Tris base 12.1 g
glycine 56.33 g
bulk methanol l 1
Adjust volume to 5 litters
Tris/Saline Buffer (pH 7.4) :
Tris base 2.42 g
NaCl 18 g
Tris/Saline with BSA
BSA 9 g
Tris/Saline 300 ml
Tris/Saline with NP 40
NP 40 0.3 ml
Tris/Saline 600 ml
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Test Sera:
12®I Staph A, about 30,000,000 cpm.
Radlolodinatlon solutions:
0.01 M Phosphate, pH 7.4.
0.1 M phosphate, pH 7.2.
Nal (125):
50 mci/ml in 0.05 N NaOH
1 % BSA:
BSA (fraction V) 1 g
0.01 M phosphate 100 ml
10 % Trichloroacetic acid
Test Dye
Blue Dextran 10 mg
Phenol red 10 mg
0.01 M phosphate 100 ml
Chloramine-T
40 mg in 10 ml 0.1 M phosphate.
Sodium Metabisulfite
50 mg in 20 ml 0.1 M phosphate.
1 % sodium iodide
100 mg in 10 ml 0.1 M phosphate.
Protein Purification Solutions:
Sonication Buffer, pH 8.0:
50 mM Tris-phosphate, 25 mM NaF, 0.1 mM EDTA, 0.5 mM 
ATP,10 mM DTT and 0.1 mM PMSF (0.5 M stock solution in ab­
solute ethanol).
Column Buffer, pH 6.0:
50 mM Tris-phosphate, 25 mM NaF, 0.1 mM EDTA, 0.1 mM 
ATP, ImM DTT and 0.1 mM PMSF.
Appendix VI 
cDNA Cloning
A. Amplification of the Lambda EAPXI Vactor library
This protocol was followed as described by Maniatis et 
al. (1982) with minor modifications.
1. A liquid culture of the XLl-Blue cells was 
started from a single colony and grown overnight 
with vigorous shaking at 37°C in LB media
supplemented with 0.2 % maltose and 10 mM MgSO^.
2. The cells were spun at 1000 x g and adjusted to an
a600 * °*5*
3. Mix aliquots of the packaged lambda amplified 
suspension containing approximately 50,000
recombinant bacteriophage with 600 Jil of XLl-Blue 
cells in 2059 Falcon tubes.
4. Incubate tubes containing phage and XLl-Blue cells 
15 minutes at 37°C.
5. Mix Each aliquot of infected bacteria with 6.5 ml 
of melted 48°C top agarose and poured evenly onto a 
1-2 day old NZY 150 mm plate of bottom agar. The 
plates were incubated at 37°c for 9 hours.
6. Pipette 10 ml of SM buffer onto each plate, the 
plates were incubated at 4°C overnight with 
vigorous shaking.
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7. The bacteriophage suspension was recovered from 
each plate and pooled into a sterile polypropylene 
tube. Chloroform was added to 5 % into each 
tube.
8. Remove Cell debris by centrifugation for 5 min at 
4000 x g.
9. Recover the supernatant, pool and transfer to a 
sterile polypropylene tube. Add Chloroform to 3 
% and store in aliquots at 4°C.
10. The titer of the amplified library was
1 1approximately 10 pfu/ml. 
cDNA screening
1. Approximately 50,000 plaques were plated with 600
p.1 Of Agpg = 0.5 XLl-Blue cells and 6.5 ml of
top agarose on a large 150 mm NZY plate. Twenty 
plates were used to screen 1 x 106 plaques.
2. The plates were incubated at 37°C for 9 hours and 
then chilled 4 hours at 4°C. Transfer Plaques 
for 2 minutes onto nitrocellulose filters labeled 
(waterproof ink). Duplicate filter were used for 
each plate, The second transfer last for 4 
minutes.
3. Nitrocellulose filters left from plates were 
submerged in 1.5 M NaCl, 0.5 M NaOH for 2 minutes 
and neutralized 5 minutes by submerging in 1.5 M 
NaCl, 0.5 M Tris-HCl, pH 8.0.
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4. Rinse Filters for 30 seconds in o.2 M Tris-HCl, pH 
7.5, 2 x SSC.
5. Blot filters dry on Whatman 3MM filter paper 
and baked at 80°C for 2 hours. Store the master 
plates wrapped with parafilm at 4°C to use for 
subsequent phage isolation.
6. Submerge the baked filters in 6 x SSC for 5 
minutes.
7 Transfer the filters to a flat-bottomed plastic 
box containing 300 ml prewashing solution and 
incubate at 42°C for 2 hours.
8. Pour off the prewashing solution. Incubate the 
filters for 4 hours at 42°C in 100 ml
prehybridization solution.
329. Denature the P-labeled probe DNA by heating to
100°C for 5 minutes. Add the denatured probe to 
the prehybridization solution covering the 
filters. Incubate at 42°C for 24 hours.
10. After the hybridization is completed, discard the 
hybridization solution. Wash the filters 3-4 times 
for 5-10 minutes each wash, in 500 ml of 2 x SSC
and 0.1 % SDS at room temperature.
11. Wash the filters twice for 1 hour in 500 ml of a
solution of 1 x SSC and 0.1 % SDS at 68°C.
12. Dry the filters in air at room temperature. Tape 
the filters onto sheets of used X-ray film and
place pieces of tape marked with radioactive ink 
at several locations on the used X-ray film.
13. Cover the filters in Saran Wrap and apply to X-ray 
film (Kodak XR) and exposed 50 hours at -70°C.
14. After development, align the film with the filters 
using the marked left by the radioactive ink. 
Identify the positive plaque by aligning the dots 
on the tracing paper with those on the agarose 
plate.
15. Use a sterile Pasteur pipette to pick up each 
positive plaque and place into 1 ml of SM 
containing a droplet of chloroform. This phage 
stock is stable for up to a year at 4°C.
C. In vivo excision
This protocol was provided by Stratagene (La Jolla, CA)
1. In a 50 ml conical tube combine:
a. 200 Hi of ODgQQ * 1.0 XLl-Blue cells.
b. 200 ill of Lambda ZAPII phage stock (containing >
1 x 10̂ ) phage particles.
c. 1 fil of R408 helper phage (1 x 1011 pfu/ml) . 
Incubate mixture at 37°C for 15 minutes.
2. Add 5 (il of 2 x YT media and incubate 3 hours at 
37°C with shaking.
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3. Heat tube at 70°C for 20 minutes, then spin tube 
for 5 minutes at 4000 x g.
4. Decant the supernatant into a sterile tube.
5. To plate the rescued phagemid, combine the
following in two 15 ml tubes:
a. 10 |il of phage stock and 200 ml A^qq = 1.0 
XLl-Blue host cells.
b. 20 jil of a 10~2 dilution of phage stock from
step 5 above and 200(11 A600 - 1.0 of XLl-Blue 
host cells. Incubate tubes at 37°C for 15 min.
6. Plate 1 to 100 (ll on LB/ampicillin plates and 
incubate overnight at 37°C.
7. Colonies appearing on the plate contain the
pBluescript double stranded phagemid with the 
cloned DNA insert. Streak the colony on a new 
LB/amp plate.
Appendix VII 
Isolation of Plasmid DNA
These protocols were adapted from Maniatis et al., (1982) 
with minor modification.
A. Large-seaIs preparation by CsCl centrifugation:
1. Inoculate 3 ml of LB medium containing the 
appropriate antibiotic with a single bacterial 
colony and grow for 8 hours.
2. Transfer 2.5 ml of the cell culture to 250 ml LB 
medium containing the appropriate antibiotic. 
Incubate at 37°C with vigorous shaking until
a600 reaches approximately 0.6, then add 1.25 ml
of chloramphenicol (34 mg/ml in ethanol).
Incubate at 37°C for 12-16 hours.
3. Harvest the bacterial cells by centrifugation at 
6000 x g for 10 minutes at 4°C.
4. Resuspend the bacterial pellet in 5 ml of solution 
I, transfer the solution to a 35 ml tube and let 
stand at room temperature for 5 minutes.
5. Add 10 ml of freshly made solution II. Cover the
top of the tube with parafilm and mix the
contents by gently inverting the tube several 
times. Let stand on ice 10 minutes.
6. Add 7.5 ml of an ice-cold solution of solution III
and let tube stand on ice 10 minutes.
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7. Centrifuge on a Sorvall roter at 20,000 rpm for 
30 minutes at 4°C.
8. Transfer equal volume of the supernatant into each 
of two 30 ml Corex tubes.
9. Add 0.6 volume of isopropanol to each tube. Mix 
well and let stand at room temperature for 15 
minutes.
10. Recover the DNA by centrifugation in a Sorvall 
roter at 10,000 rpm for 30 minutes at room 
temperature.
11. Discard the supernatant. Wash the pellet with 70 
% ethanol at room temperature, then dry the DNA 
pellet briefly in vacuum desiccator.
12. Dissolve the pellet in a total volume of 4 ml of 
TE.
13. For every ml of DNA solution add exactly 1 g of 
solid cesium chloride.
14. Add 0.8 ml of a solution ethidium bromide (10
mg/ml in Î O) for every 10 ml of cesium chloride
solution. Mix well. The final density should be 
1.55 g/ml.
15. Transfer the CsCl solution to a clear 
ultracentrifugation tube and fill the remainder of 
the tube with light paraffin oil.
16. Centrifuge in a Beckman Type-65 roter at 45,000 
rpm for 20 hours.
17. Remove the cap from the tube. Collect the lower
band of DNA into a orange cap tube through a #18
needle inserted into the side of the tube.
18. Remove the ethidium bromide by adding equal volume 
of 1-butanol saturated with water. Centrifuge at 
1500 x g for 3 minutes at room temperature.
19. Transfer the lower aqueous phase to a clean tube. 
Repeat the extraction 4-6 times until all the 
pink color disappear from the aqueous solution.
20. Dialyze the aqueous phase against 3 changes of TE.
Mini-preparation procedure:
1. Pour 1,5 ml of overnight cell culture into an
eppendorf tube. Centrifuge for 2 minutes at room 
temperature. Drain the supernatant.
2. Resuspend the pellet in 100 jil of ice-cold 
solution I and let stand at room temperature for 
5 mins.
3. Add 200 p.1 of solution II. Mix the contents in 
the tube by inverting the tube several times.
Let stand on ice for 5 minutes.
4. Add 150 Hi of solution III. Mix the contents in 
the tube by inverting the tube sharply several 
times. Let stand on ice for 5 minutes.
5. Centrifuge at 4°C for 5 minutes and transfer the 
supernatant to a fresh tube.
Add 0.5 ml of phenol/chloroform (1:1), vortex and 
let stand for 2 minutes. Centrifuge at room 
temperature for 5 minutes and transfer the 
supernatant to a fresh tube.
Add 1 ml of ethanol and let stand at room 
temperature for 5 minutes, then centrifuge at 
room temperature for 5 minutes.
Hash the pellet with 1 ml of 70 % ethanol and 
centrifuge at room temperature for 5 minutes. 
Remove ethanol and dry the pellet briefly by 
vacuum.
Dissolve the DNA pellet in 10 |Al of TE (pH 8.0) 
Use 5 ill for each digestion reaction.
Appendix VIII 
DMA Fragment* Subcloning
A. Isolation of tba DNA fragment form low melting 
agarose gel
This is a protocol provided by the Geneclean Kit 
with minor modification.
1. Digest interested DNA and the cloning vector with 
appropriate restriction enzymes, then inactivated 
the enzymes by heating at 70°C for 10 minutes,
2. Prepare 0.8 - 0.6 % low melting agarose gel in 50 
mM Tris-acetate (TAE) buffer.
3. Load the digested samples onto the gel. The 
target DNA fragment can be visualized under long
wavelength UV light by staining the gel with 0.5
t*g/ml of ethidium bromide for 20 minutes after 
gel electrophoresis.
4. Excise the DNA fragment from the gel and incubate 
the gel slice at 45°C to 55°C for 5 minutes.
5. Add 2.5 x volume of Nal stock solution, mix the 
contents in the tube and further incubate the 
tube at 45°C to 55°C for 3 minutes.
6. Add 5 ill of Glassmilk suspension, vortex and place 
on ice for 5 minutes.
7. Pellet Glassmilk/DNA complex for 5 seconds.
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8. Wash pellet 3 times with New solution. Add 500
|il of ice-cold New solution to the pellet for each 
wash.
9. Spin the tube for a few seconds and remove the
last bit of liquid with a pipette tip.
10. Elute DNA into 10 |il of H20. Incubate the tube at 
45°C to 55°C for 3 minutes.
11. Centrifuge for 30 seconds to make a solid pellet 
and carefully transfer the supernatant containing 
the eluted DNA to a fresh tube.
B. Ligation reaction
insert DNA x (11 (molar rate of vector: insert*l: 5)
vector DNA y Hi
10 x ligation 2 |ll 
buffer
T4 DNA ligase 1 U 
H20 to 20 Hi
The reaction mixture is incubated at room 
temperature for 4 hours.
C. Preparation of Proxen Competent Celia
The protocol described here is similar to that 
described by Hanahan (1983).
1. Inoculate a fresh single colony into 2 ml LB 
medium and grow for overnight.
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2. Transfer 0.25 ml of overnight cell culture to 25 
ml of SOB medium in a 500 ml Erlenmeyer flask.
3. Incubate at 37°C with moderate agitation until the
cell density is O*D.gg0 = 0.4 - 0.5.
4. Collect the culture into 50 ml polypropylene 
centrifuge tube and chill on ice for 15 minutes.
5. Pellet the cells by centrifugation at 3000 r.p.m. 
in a clinical centrifuge for 15 minutes at 4°C. 
Drain the pelleted cells thoroughly by inverting 
the tube on paper towels, and rapping to remove 
any liquid.
6. Resuspend the cell pellet by moderate vortexing 8 
ml of RF1. Incubate the cells on ice for 15 
minutes. Pellet cells as in step 5.
7. Resuspend the cells in 2 ml of RF2. Incubate the 
cells on ice for 15 minutes.
8. Distribute 200 pi aliquots into chilled 
microcentrifuge tubes.
9. Freeze in a solid C02/alcohol bath, then place at 
-70°C.
D . Transformation procedure
This protocol is similar to the procedure of using
frozen competent cells described by Hanahan (1983).
1. Mix 200 JjLI of competent cells with 3 Hi
ligation reaction into chilled eppendorf tube
by moving pipette tip through cells while 
dispensing; then gently tap tube to mix. 
Incubate cells on ice for 30 - 60 minutes.
Heat shock at 42°C for 90 seconds. Place tube 
on ice.
Add 0.8 ml of room temperature LB medium and 
shake at 225 r.p.m. for 1 hour at 37°C.
Plate on LB or 2 x YT plates containing the 
appropriate antibiotics. Incubate plate 
overnight at 37°C.
Appendix IX 
ExoXII/Mung Bean Nuclease Deletions
These protocols were followed as described in Stratagene 
manual.
A. Digestion of clones of interest
1. Use CsCl purified double-stranded DNA.
2. Double digest clones to completion with a 
unique 3' overhang restriction site and a 
unique 5# or blunt restriction site that must 
lie between the insert and the 3' site chosen.
3. Check for completion of first digestion on an 
agarose gel.
B. ExoIII/Hung Delations
1. A stop solution is prepared for each ExoIII time
point. Dilute 20 Jil of 10 x Mung Bean Buffer
into 155 M-l of H2O in an eppendorf tube for each
time interval desired.
2. The reaction is started by adding 20 U of ExoIII
for each 1 îg DNA. Incubate reaction at 30°C
(delete 230 bp/minute) and remove 25 Jil aliquots 
from the reaction mixture at the appropriate time
intervals. Add the 25 |il aliquot directly to a 
tube containing the 175 jil aliquots of diluted
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Mung Bean Nuclease Buffer prepared before 
starting the ExoIII reactions and place on dry 
ice.
For each time point the reaction contains:
double-digested DNA 5 pg
2 x Exo buffer 12.5 pi
fresh 100 mM p-mecaptoethanol 2.5 pi
Exonuclease III 20 U
H20 to 25 pi
When all the aliquots have been removed, heat 
tubes at 68°C for 15 minutes, and then place on ice. 
Add 15 U of Mung Bean Nuclease to each time point 
tube and incubate for 30 minutes at 30°C.
Add:
1 M Tris-Cl, pH 9.5 10 Ml
0 M LiCl 20 Ml
20 % SDS 4 Ml
phenol:chloroform 250 Ml
Vortex, spin 1 minute in microfuge, remove upper 
aqueous layer and extract the upper layer with 
chloroform.
Add 25pi 3 M sodium acetate, pH 7.0 to the 
aqueous phase.
8. Add 0.65 ml of cold ethanol. Chill on dry ice 10
mins and spin in a microfuge for 20 minutes.
9. Drain off the supernatant and wash the pellets 
with 80 % ethanol. Dry the pellet,
10. Redissolve DNA pellet in 15 pi of TE.
11. Ligate DNA deletions using the following
conditions:
ExoIII/Mung treated DNA 1 pi
10 x ligation buffer 2 pi
5 mM ATP, pH 7. 0-7.5 2 pi
T4 DNA ligase 2 pi
H20 to 20 p.1
12. Seven pi of the remaining 14 pi of ExoIII/Mung 
treated DNA is used for gel electrophoresis 
analysis.
13. Use 1 pi of the ligation reaction to transform 200
pi of JM109 competent cells.
Quick screen of CxoIII/Mung transformants
1. Isolate 3-4 colonies from each time interval with 
sterile toothpick and streak each as a single line 
onto LB/amp plates.
2. Grow overnight at 37°C.
Scrape bacteria with sterile toothpick and 
resuspend in 40 |il of 1 x STE
Add 40 pi of phenol:chloroform and vortex.
Microfuge 1 minute.
Transfer supernatant to eppendorf tube and add 1 
pi of RNaseA (1 mg/ml).
Wait 2 minutes. Load 20 pi onto 1 % agarose gel 
and electrophoresis to compare supercoiled Exo/Mung 
deleted plasmids.
Appendix X.
Sequencing Double Stranded end Single Stranded DNA Using
Sequenase Kit
A. Clean up and denaturation of plasmid DNA
This is a protocol provided by personal 
communication from Dr. Lo.
1. Add 6 |ll of RNaseA (10 mg/ml) to 5 |ig of DNA in
300 |ll of low TE buffer and incubate at 37°C for 
30 minutes.
2. Add 3 |ll of Proteinase K and 15 |ll of 10 % SDS 
into the tube and incubate at 37°C for further 30 
mins.
3. Extract with phenol/chloroform twice. Transfer 
the aqueous phase to a fresh tube.
4. Add 150 |ll of 7.5 M NH4OAc (pH 7.5) and 900 |ll of
ice-cold ethanol. Incubate on ice for 30 minutes.
5. Microcentrifuge at 4°C for 10 minutes. Dry the 
pellet by vacuum.
6. Redissolve the pellet in 64 |il of low TE (pH 8.0).
7. Add 16 |il of 5 x denaturing buffer (0.4 g NaOH +
20 ml 0.5 M EDTA pH 8.0, in 10 ml H20), mix and
incubate at room temperature for 5 minutes. 
Transfer to ice.
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8. Add 15 ml 2 M NH4OAc {pH 4.5) and 220 *11 ethanol,
mix and let stand in -70°C freezer for 30 minutes.
9. Centrifuge the DNA tube at 12,000 r.p.m.20 mins at 
4°C
10. Wash the pellet with 70 % ethanol and recentrifuge 
for 10 minutes.
11. Vacuum dry the pellet and use immediately or store 
at -20°C as dry pellet.
B. Single stranded DMA preparation
a) Preparation of Ml3 single stranded DNA template
1. Inoculate a single colony of DH5aFf into 2 ml 2 x
YT medium and grow overnight at 37°C.
2. Transfer 30 jil of overnight cell culture to 3 ml
2 x YT and add 5 nl of phage stock to infect the 
cells. Grow cells at 37°C for 5 hours.
3. Transfer 1.5 ml of the cell culture to an 
eppendorf tube and centrifuge for 5 minutes.
4. Pour the supernatant to a fresh eppendorf tube and
add 200 Hi of 20 % PEG/2.5 M NaCl.
5. Vortex the supernatant well and let stand at room 
temperature for 30 minutes.
6. Centrifuge the tube and remove supernatant 
completely.
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7. Resuspend the phage pellets and combine two tubes 
in 100 Hi TE.
8. Add 100 p.! of TE (pH 8.0) saturated phenol, vortex 
well, and let stand at room temperature for 2 
minutes.
9. Transfer the aqueous phase to a fresh eppendorf 
tube, add 1/10 volume of NaOAc (2.5 M) 2.5 volume 
ethanol, and precipitate at -70°C for 30 minutes.
10. Centrifuge at 4°C for 15 minutes and pour out the 
supernatant. Wash the pellet with 70 % ethanol and 
vacuum dry.
11. Dissolve the pellet in 20 H1 of TE <PH 8.0).
12. Load 3 Hi onto a 0.8 % agarose gel. Check the
purity and concentration by comparing to the M13 
ssDNA provided by Sequenase kit.
b) Isolation of single stranded DNA from cells 
containing phagemids
This is a protocol provided by Stratagene for 
rescuing ssDNA with minor modifications.
1. Grow an overnight culture containing phagemid DNA 
in XLl-Blue or JM109.
2. Transfer 0.3 ml of cell culture to 3 ml TYP medium
and shake at 37°C in a sterile 50 ml conical tube.
Add R408 helper phage during log phase (OD600 *
0.3) at a multiplicity of infection of 20:1 (phage 
to cells). Continue shaking for 8 hours.
Transfer the culture to an eppendorf tube. Spin 
down cells for 1-2 minutes in a microfuge, 11,000 
x g, room temperature.
Transfer 1.2 ml of the supernatant to a fresh
eppendorf tube and add 300 M-l of a 3.5 M NH40Ac
(pH 7.5)/20 % PEG solution. Invert to mix, and let 
stand at room temperature for 15 minutes.
Spin the tube for 20 minutes at 11,000 x g in 
microfuge. Thoroughly remove the supernatant.
Spin again for 1 minute and remove any remaining 
supernatant.
Resuspend the pellet in 300 )il TE (pH 8.0). Add
300p.1 buffer-saturated phenol/chloroform, vortex 
for 1 minute, and spin for 1 minute in microfuge. 
Remove the top aqueous phase and transfer to a 
fresh tube. Repeat the extraction until there is
no interface left. Add 300 )il chloroform, vortex 
for 1 minute and spin for 2 minutes. Transfer the 
aqueous phase to a fresh tube.
Precipitate the ssDNA by adding 200 ill 7.5 M
NH^OAc and 800 jil of cold ethanol. Leave on ice
for 15 mln. Spin for 20 minutes# 11,000 x g, 4°C. 
Drain the supernatant and carefully wash the 
pellet with 80 % ethanol. Vacuum dry and dissolve
the pellet in 20 jil TE
Analyze ssDNA on a 0.8 % agarose gel.
Preparation of a 6 % sequencing gel
Clean the glass plates well and siliconize the 
inner side of small glass plate the previous day 
of gel electrophoresis.
Wash away the remaining siliconizing solution with 
distill water and let it air dry.
Wipe the glass plates with 95 % ethanol. Place 
the spacers and arrange the glass plates, clamp on 
two long sides.
Degas 80 ml 6 % gel mix for 20 minutes at room
temperature. Add 234 Hi Of 10 % ammonium
persulfate and 21 pi TEMED to initiate the 
polymerization reaction.
Mix the gel solution well and pour it between 
the glass plates. Put the 0.4 mm comb in place. 
Let it polymerize for 5-40 minutes.
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E. Dideoxy sequencing reaction
This step-by-step protocol is provided by USB for 
DNA sequencing with Sequenase.
1. Primer annealing
for each reaction mix:
5 x sequenase buffer 2 nl
ssDNA template 1 |ig ( 5 |ig dsDNA) x ill 
primer y ill
H20 to 10 |xl
Mix and incubate at 65°C for 30 minutes, and 
gradually cool at room temperature to < 35°C.
During this cooling time,
1) Label G, A, T, C tubes. Aliquot 2.5 ill of the 
dideoxy termination mixes into these tubes, 
before use, warm up to 37°C.
2) Dilute the labeling mix 1 : 5 by double distilled 
water.
3) Measure 8 Jll Sequenase dilution buffer and keep
on ice. Add 1 111 sequenase and mix just before 
use.
4) Take the dATP out of freezer and warm it 
inside fumehood for about 20 minutes.
5) Prerun the gel at 1500 volts 20 mAmp for 15 
minutes. This will help wash urea and warm up 
the gel.
2. Labeling and Termination
Add to the primer annealed DNA 10 Hi
Diluted labeling mix 2 |il
0.1 M DTT 1 nl
35S dATP (10 HCi) 0.5 Hi
Incubate at room temperature for 2-3 minutes.
Aliquot 3.5 H* of the labeling reaction to each 
of the Gf A, T, C termination tubes and incubate
at 37°C for 5 minutes. Add 4 h* stop solution 
to each tube. Keep the tubes on ice.
Running, fixing, drying and exposure of the gel
1. Heat the tubes at 95°C for 3 minutes and keep on 
ice.
2. Wash the wells with 0.5 x TBE before loading the
sample. Load 3 H1 Per well; load one set of G,
A, T, c samples at a time.
3. Stop the running of the gel when the fast dye 
reaches the bottom of the gel.
4. Cool the gel for 10 minutes and remove the small 
glass plate.
Fix the gel in 1 litter of 10 % acetic acid and 12 
% methanol for 30 minutes and siphon out the 
fixing solution.
Put a Piece of 3MM Waterman paper onto the gel and 
gently take out the gel from the glass plate Cover 
it with Saran wrap.
Place in drier and dry it at 80°C for 40 minutes.
After complete drying, remove Saran wrap and
expose to Kodak X-OMAT AR film at room 
temperature overnight.
Jtppwtdix XI.
Radioiodination of Protains with Chloramina-T 
Preparation of Sephadex G-25
To prepare enough Sephadex for 10 columns (10 
iodinations), weigh about 20 g of dry Sephadex into 
a 250 ml beaker.
Slowly add about 100 ml 0.01 M phosphate. Gently 
swirl the resin to remove large pockets of air.
The gel requires at least 3 hours at room 
temperature to swell completely.
Rinse the resin by carefully decanting the 
original buffer after the resin has settled for 
about 1 hour and replacing it with fresh buffer. 
This should be repeated at least twice. The final 
ratio of buffer to resin should be about 1.5.
Store the swollen resin at 4°C.
Preparation of Sephadex G-25 gel filtration column 
The column consists of a 10 ml glass disposable \ 
pipette.
Affix a short (about 1 cm) piece of thin 
Tygon/tubing to the tip of the pipette.
Cut the tip off an 18 gauge needle, then cut a 1.5 
cm length from the same needle. Slip the needle 
with base onto the outlet of the stopcock, then
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attach about 12 inches of Tygon tubing.
Fit the second piece of needle to the tubing.
4. Plug the bottom of the pipette with glass wool.
C. Radioiodination of proteins
To perform the reaction: All the following steps 
should be done in a fumehood on ice.
1. Add 0.5 or 1 mCi Nal (125) to the protein 
sample.
2. To initiate the reaction, add 20 p.1 of the 
Chloramine-T solution and mix well.
3. Time the reaction for 3 minutes.
4. To terminate the reaction, add 100 p.1 of the 
sodium metabisulfate solution and mix well.
5. In order to minimize noncovalent binding of
1-125 to proteins, add 200 p.1 of carrier sodium 
iodide solution and mix well.
D. Gal filtration of the radiolabeled protein
1. Open the stop cock on the column and allow the 
buffer to just reach the top of the packed bed. 
Very gently apply the reaction mixture to the top 
of the column bed and allow it to soak 
completely into the column bed before adding more
0.01 M phosphate to elute the column.
2. As soon as the reaction mixture is applied to the
column, begin collecting fractions —  15 drops or
about 0.3 ml per fraction. Collect at least 40 
fractions before stopping the column and closing the 
stopcock.
Count 5 pi aliquots of each fraction in the auto 
gamma counter. Plot the data and pool 
appropriate fractions —  iodinated protein should 
elute early (12-18 fractions) and free iodine and 
other salt elute late (23-40 fractions). Measure 
the total activity and volume of the pooled 
fractions.
To keep the iodinated proteins from possible
aggregating and falling out of solution, add 10 p.1 
of 10% Deoxycholate to the pooled fractions.
Store at -20°C.
Determination of covalently-bound 1-125
Add I0p.l of 1 mg/ml BSA to 5 Hi of the iodinated 
protein in an eppendorf tube. Count this in the 
gamma counter.
Add 900 Hi of 10 % TCA that has been chilled and 
incubate on ice for 20-30 minutes to facilitate 
protein precipitation.
Centrifuge for 10 minutes in the eppendorf 
centrifuge 12,000 x g, preferably at 4°C.
Carefully pipette out the supernatant and count
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the pellets in the auto gamma counter. Calculate 
% TCA precipitability
A p p e n d i x  X I I  
Western Blotting
This procedure was taken directly from W. N. Bur- 
, Ana. Biochem. 112, 195-203, 1901.
Transfer the proteins from a SDS-PAGE to the 
nitrocellulose membrane.
Block the membrane in ISO ml Tris/saline with BSA 
at 37°C for 30 minutes.
Treat the membrane with the diluted rat anti-PFK 
antibody in 60 ml Tris/saline with BSA at room 
temperature for 90 minutes.
Remove the test serum by multiple washes as 
follows: first, wash for 10 mins with 100 ml 
Tris/saline followed by two 20 mins washes with 
150 ml Tris/saline with NP 40 and finally for 10 
mins in 150 ml saline.
i petreat the membrane with the steph A.
Hash the membrane as step 4.
The treated membrane is briefly blotted dry 
between several paper towels and placed in a film 
cassette and allowed to expose to a piece of Kodak 
XAR-5 x-ray film for 3-18 hours at -70°C.
Appendix XIII 
Altered Sites In Vitro Mutagenesis System
A. Cloning into tha pSCLECT-1 Vactor
B. Praparation of Phaganid Singla-Strandad DNA
1. Prepare an overnight culture of cells containing 
pSELECT-1 or pSELECT-control phagemid DNA.
(TYP/Tc 15 jig/ml)
2. Use 1:50 dilution of overnight culture to 5 ml
TYP <Tc 15 lig/ml) .
Shake vigorously at 37° C for 30 min. in a 50 ml 
tube.
3. Add 40 jil of R408 helper phages to the 5 ml 
culture. Continue shaking for 6 hours to overnight 
with vigorously agitation.
4. Pellet the cells at 12,000 x g for 15 min. Pour
the supernatant into a fresh tube and spin again for
15 min.
5. Add 0.25 volume of 3.75 M ammonium acetate 
(pH 7.5)/20% PEG. Leave on ice for 30 min.
Centrifuge for 15 min. at 12,000 x g.
6. Resuspend the pellet in 400 111 of TE and transfer 
the sample to a microcentrifuge tube.
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7. Add 0.4 ml of chloroform:isoamyl alcohol (24:1) to 
lyse the phage, vortex for 1 full min., centrifuge 
at 12,000 x 9 for 5 min.
8. Add 0.4 ml of TE-saturated phenol:chloroform to 
the aqueous phase, votex for 1 full min. Centrifuge 
for 5 min.
9. Repeat the phenol extraction several times until 
there is no visible material at the interface. ('5 
times)
10. Add 0.5 volume (200 ill) of 7.5 M ammonium acetate
+ 2 volumes of ethanol. Leave at -20°C for 30 min.
11. Centrifuge at 12,000 x g for 5 min, rinse the 
pellet with 70% ethanol. Dry the DNA pellet.
12. Resuspend the DNA in 20 |il of HgO. Estimate the
amount of DNA. (R408 is 6.4 kb, pSELECT is 5.6 kb)
C.Mutagenesis Procedure
a. Annealing reaction and mutant strand synthesis
1. Mutagenesis annealing reaction:
Recombinant pSELECT-1 ssDNA 0.05 pmol
Ampicillin repair oligo (2.2 ng/ml) 1 Jil (o.2 5pmol) 
Mutagenic oligo phosphorylated 1.25 pmol
10X Annealing buffer 2 p.1
H20 to 20 ill
Control annealing reaction!
pSELECT-control ssDNA 100 ng {0.05 pmol)
Ampicillin repair oligo 1 |il (0.25 pmol)
lacZ control oligo (10.0 ng/ml) 1 Ml (1.25 pmol)
H20 to 20 m
2. Heat the annealing reaction to 70°C for 5 min. and 
allow it to cool to room temperature.
3. Place the annealing reaction on ice and add the
following:
10X synthesis buffer 3 |il
T4 DNA polymerase 1 p.1
T4 DNA ligase 1 pi
H20 to 30 1̂
4. Incubate the reaction at 37°C for 90 min. 
Transformation into 8MH 71-18 mut S
1. Add 3 Ml of DMSO to 200 Ml of BMH 71-18 mut S 
competent cells, mix briefly, and then add the 
entire synthesis reaction.
2. Let the cells sit on ice for 30 min. (Heat shock at
10X Annealing buffer 2 Ml
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3. Add 4 ml of LB broth and incubate at 37°C for 1
hour. (1 ml of the culture can be removed and
spreaded on LB/ampl25 plate)
4. Add ampicillin to a final concentration of 125 Hg/ml 
and incubate at 37°C for 12-14 hours with shaking.
c. Mlni-prep plasmid DNA
d. Transformation into JM109
1. Add 3 )il of DMSO to 200 |il of JM109 competent
cells, mix briefly, and add 100 ng of mutagenized 
DNA.
2. Let the cells sit on ice for 30 min. Heat shock at 
42°C for 1-2 min.
3. Add 2 ml of LB broth and incubate at 37°C for 1 
hour.
4. Divide the culture into two microcentrifuge tubes.
5. Spread the cells in each tube on an LB/ampl25 
plate.
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